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GENERAL INTRODUCTION 
 
 The immune response requires the coordinated function of many cell types to 
appropriately execute successful defense against extracellular pathogens, infected cells 
and malignancies.  An intricate balance exists between immune activity to clear disease 
and immune suppression to avoid excessive damage.  While rapid and robust induction 
is necessary to clear the body of destructive pathogens, an over-exuberant response 
can be equally dangerous.  When left unchecked an overactive immune system 
develops into autoimmunity, leading to the destruction of normal tissue and the onset of 
diseases such as diabetes mellitus, Hashimoto’s thyroiditis and multiple sclerosis 
among many others.  Under these circumstances treatments are directed at 
suppressing the immune response.  On the other hand, treatment of late stage 
malignancies often requires elimination of immune suppression to boost anti-tumor 
activity (76).  During the onset of cancer the immune system is able to recognize and 
attack malignant cells; if unsuccessful in clearing the malignancy, the relationship 
between tumor and immune system shifts in favor of tumor tolerance, a process 
referred to as immunoediting (35). 
 Current therapies for a variety of disorders take advantage of the immune 
response by either targeting activation or suppression pathways.  The co-stimulatory 
molecule cytotoxic lymphocyte associated factor 4, or CTLA-4, acts to control T cell 
proliferation (116), making it an excellent therapeutic target.  CTLA-4 was first 
discovered in mouse CD8 T cells and its expression was thought to be restricted to 
activated T and B cells (18).  Soon after a human homologue was found and shown to 
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be structurally similar, indicating these may be the same protein in these two species 
(33).  The CTLA-4 protein is a 223 amino acid T cell surface molecule with an 
extracellular domain, transmembrane region and short cytoplasmic tail.  In humans the 
CTLA-4 gene is located on chromosome 2, just over 100kb away from the activating 
receptor CD28, suggesting the CTLA-4 gene may be the result of a duplication event 
(44, 58).  CTLA-4 and CD28 share about 20-30% sequence homology, particularly in 
exon 2 where the hexapeptide MYPPPY is found on both proteins (23, 58).  They each 
form homodimers and both interact with antigen presenting cell molecules CD80 and 
CD86, collectively known as B7 (100, 105).  However, CTLA-4 binds B7 with at least 
10-fold higher avidity (63), which is probably due to its bivalent interaction with B7 
versus the monovalent binding of CD28 (100, 105).  This phenomenon allows negative 
T cell regulation to take priority over activation.   
 The CTLA-4 gene is induced in effector CD4 and CD8 cells upon activation (94), 
however we detect higher expression levels in memory CD4 populations than CD8 
following stimulation (unpublished data).  Regulatory T cells (Tregs), which maintain 
peripheral tolerance and control immune activation, constitutively express CTLA-4 on 
their cell surface, again demonstrating the role of this gene in immune response control 
(55, 101, 108).  The distinctive methods of expression between regulatory and effector 
T cells are not well understood; it would be valuable to elucidate what properties direct 
constitutive versus inducible activation.  This work focuses on regulation of the inducible 
CTLA-4 in human CD4 T cells. 
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Effects of CTLA-4 dysfunction in mouse models and human disease.  The critical 
role CTLA-4 plays in immune regulation becomes clear when this gene is knocked out 
in an animal model.  Transgenic mice suffer severe lymphoproliferation and infiltration 
leading to multi-organ failure and death within 3-4 weeks (111, 123).  Target organs 
include liver, heart, lung and pancreas.  Knockout T cells proliferate rapidly and 
robustly, supporting CTLA-4’s function as a braking system for T cells which helps 
maintain homeostasis in the adaptive immunity.  The T cell receptor (TCR) associated 
tyrosine kinases FYN, LCK and ZAP-70 are robustly activated in the transgenic mice 
(72).  Addition of CTLA-4 immunoglobulin (Ig) can block the lymphoproliferative effects 
in CTLA-4 -/- mice, but this therapy does not have long-term function as T cell activation 
resumes upon removal of the Ig (112). 
 In humans, CTLA-4 dysregulation has been linked to autoimmunity.  
Polymorphisms of CTLA-4 have been discovered, including three within non-coding 
promoter or regulatory regions at positions -1722, -1661, and -318, one within exon 1 at 
position +49 and a dinucleotide repeat microsatellite within the 3’ UTR.  These 
abnormalities correlate to various immune-mediated diseases including Grave’s, 
systemic lupus erythematosus, Hashimoto’s thyroiditis and type 1 diabetes, again 
implicating its essential role in normal human immune function (9, 56, 61).  While the 
three non-coding polymorphisms likely affect transcription efficiency, the A49G 
substitution is within the signal sequence and results in atypical processing by the 
endoplasmic reticulum and thus reduced surface expression (4).    A study by Huang, et 
al demonstrated the impact of the AT repeat on T cell activity, showing the length of the 
repeat was proportional to serum IL-2 levels in their specimens and PBMC isolated from 
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patients with longer repeats were more proliferative upon stimulation of the TCR and 
CD28.  Those with longer alleles were also more prone to myasthenia gravis 
development (49).  Taken together, these studies have shown the impact dysfunctional 
CTLA-4 can have on immune modulation. 
 Splice variants also exist for CTLA-4 and each has an influence on function.  
Mice may express a variant lacking exon 2, but humans do not generate this protein.  
Removal of exon 3, where the transmembrane region is located, results in a soluble, 
secreted form (sCTLA-4).  This transcript has been detected in B cells and unstimulated 
T cells (69, 80).  Upon activation, the level of sCTLA-4 decreases in T cells, which then 
begin to favor the full transcript form.  The protein was still capable of binding B7 and 
inhibiting PBMC proliferation in a mixed leukocyte reaction.  Basal levels of sCTLA-4 
were measured in a percentage of normal donor sera.  Interestingly, in patients with 
autoimmune thyroid disease, which includes Grave’s disease and Hashimoto’s 
thyroiditis, the level of serum sCTLA-4 is significantly higher (79).  Similar findings were 
reported for systemic lupus erythematosus (66).  A less characterized splice form 
containing only exons 1 and 4 is also found in T cells (113).  Given that this protein 
lacks both the transmembrane and B7 interacting regions, it is not clear what the 
physiological function might be or whether dysregulation of mRNA processing to favor 
this variant may contribute to disease. 
 Aside from autoimmunity, where decreases in functional CTLA-4 are observed, 
CTLA-4 can also play a role in tumor biology.  In the case of cutaneous T cell lymphoma 
(CTCL), a malignancy of skin-homing T cells, CTLA-4 is up-regulated in the tumor 
population (13, 126).  This phenomenon could in part explain the reduced cytokine 
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production seen in later stages of the disease (29).  CTCL may serve as a direct 
example of a tumor population mediating immune response through CTLA-4.  It is 
unclear if this gene is regulated abnormally in other malignancies.  
 
Mechanisms of T cell suppression by CTLA-4.  There are two distinct processes by 
which CTLA-4 exhibits its suppressive activity.  Through its high efficiency interaction 
with B7 molecules, CTLA-4 sequesters local B7 to prevent stimulation of nearby T cells 
(82).  By use of a CTLA-4 mutant lacking the cytoplasmic tail, Carreno et al show B7 
binding is sufficient for suppression of IL-2 production and the level of suppression is 
proportional to the density of CTLA-4 on the cell surface (22).  This not only highlights 
the importance of B7 binding, but shows the level of surface CTLA-4 can be important in 
immune regulation. 
 In addition to antagonistic competition for B7, multiple studies have shown that 
the CTLA-4 cytoplasmic tail contributes to inhibitory signal transduction, but the exact 
mechanisms remain elusive.  A ligand-independent mutant of CTLA-4 was able to 
reverse the hyperreactivity of CTLA-4 -/- T cells; proliferation, cytokine production and 
TCR-mediated ERK activation were significantly reduced (26).  Current research 
attributes CTLA-4 inhibitory signaling to a combination of dephosphorylation of TCR 
and TCR-associated kinases, binding and trapping of phosphatidylinositol 3-kinase 
(PI3K) and inactivation of Ras signaling (27, 93, 109, 110).  As CTLA-4 lacks intrinsic 
enzymatic activity within its cytoplasmic tail, it is likely a series of enzymes interact with 
CTLA-4 to mediate regulatory functions. 
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 After T cell activation, CTLA-4 binds to the TCR chain and recruits tyrosine 
phosphatase SHP-2 to remove phosphate groups from TCR (60).  Both CTLA-4 and 
CD28 cytoplasmic tails contain Src homology 2 (SH2) domains with a similar tyrosine-
containing domain.  CTLA-4 is also known to cooperate with phosphatidylinositol 3-
kinase (PI3K) at the YVKM motif of SH2 on the cytoplasmic tail with similar affinity to the 
interaction with the CD28 motif YNMN (98).  A follow-up study reported phosphorylation 
of the tyrosine in the CTLA-4 YVKM domain by resting lymphocyte kinase (Rlk) is 
necessary and sufficient for PI3K interaction (99).  It is thought that CTLA-4 binds to 
PI3K and prevents its contact with CD28.  Tyrosine phosphorylation is not required, 
however, to block IL-2 production, indicating CTLA-4 utilizes its multiple inhibitory 
mechanisms to regulate T cell response (10). 
 Beyond TCR kinase activation, Ras is also induced upon T cell stimulation.  The 
serine/threonine phosphatase PP2A, which downregulates the Ras/ERK pathway, 
associates with CTLA-4 and may affect T cell activation (31).  However, the regulatory 
subunit of PP2A interacts with a 3-lysine repeat on the CTLA-4 cytoplasmic tail and 
inhibits repression by CTLA-4 as measured by IL-2 production (11).  PP2A also 
interacts at a similar domain on the cytoplasmic tail of CD28 and the exact mechanism 
of activity remains unclear (31).  The Ras pathway is also regulated by CTLA-4 through 
interaction of tyrosine phosphatase SYP at the YKVM domain of the CTLA-4 
cytoplasmic tail (72).  The Ras regulator p52SHC is shown by Marengere et al to be 
dephosphorylated upon SYP/CTLA-4 interaction.  Simply transducing the cytoplasmic 
domain has proven effective in the prevention of collagen-induced arthritis, 
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demonstrating the compelling potential of signaling regulation through the cytoplasmic 
tail (28). 
Control of CTLA-4 activity by intracellular trafficking.  Appropriate surface CTLA-4 
levels are regulated by trafficking between the cell membrane, endosomes and 
lysosomes.  Though previous studies have implied unstimulated T cells express CTLA-4 
in intracellular stores which are quickly transported to the surface upon activation (53), 
these experiments used cell clones that were cultured with IL-2 and CD3 antibodies, 
thus activating the cells.  A report by Linsley, et al developed monoclonal antibodies to 
CTLA-4 and found surface expression in resting cells was undetectable, as was mRNA 
transcript (64).  In fresh unstimulated primary cells from normal donors we have 
observed CTLA-4 protein levels are undetectable both at the cell surface and within 
intracellular stores.  We have also found transcriptional regulation mediates protein 
expression, which does not begin until cells are activated.  Regardless, it is clear that 
transport to and from the cell surface is an extremely important and highly regulated 
process through which T cells control to what degree CTLA-4 becomes involved in the 
immune response. 
 Internalized CTLA-4 is located near the microtubule-organizing center (MTOC), 
where it can be rapidly polarized to the site of cell-cell interaction upon TCR 
engagement (62).  Recruitment of CTLA-4 is highly dependent on the strength of TCR 
signaling (37).  Low levels of stimulation do not induce CTLA-4 localization to the cell 
membrane, but strong signaling does.  As CTLA-4 functions as an immune suppressor, 
it is intuitive that it would only be required during potent T cell activation.  
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 The transient surface expression of CTLA-4 is the result of concerted surface 
budding and internalization into endosomes.  CTLA-4 mRNA is targeted to and 
processed by the rough endoplasmic reticulum and the protein is glycosylated by the 
Golgi complex to form dimers (18, 33).  While in the Golgi, CTLA-4 interacts with 
clathrin adapter complex AP-1 at the YVKM motif in the SH2 region of the CTLA-4 
cytoplasmic tail (97).  The AP-1 molecule is involved in transport of excess CTLA-4 to 
the lysosome for destruction.  CTLA-4 interacts at the same motif with the 2 subunit of 
adapter AP-2 at the cell surface, but only when the cytoplasmic tail tyrosine residues 
are not phosphorylated (102).  Interestingly, the phosphorylated cytoplasmic tail is 
capable of interacting with SYP and PI3K, and therefore the phosphorylated species 
remains on the cell surface (131).  Phosphorylation can be mediated by members of the 
Src family of tyrosine kinases FYN, LYN and LCK, which may ultimately control whether 
CTLA-4 remains on the cell surface (17, 74). 
 The medium chain subunit of AP-2, AP50, also interacts with the YVKM domain 
in an unphosphorylated state and has been shown to direct internalization into 
endosomes (131).  Tyrosine mutation of the CTLA-4 cytoplasmic tail abrogates AP50 
interaction and leads to accumulation on the cell surface (30).  Upon internalization, 
CTLA-4-containing endosomes traffic to the lysosome (81), but degradation is not 
inevitable.  Instead, if the cell is appropriately activated the lysosome takes on a 
secretory function, thus recycling CTLA-4 for reuse to control the immune response (15, 
51).  The typical half-life of CTLA-4 protein is approximately 2 h (37, 81). 
 
9 
 
 
Therapeutic targeting of CTLA-4.  Standard autoimmune therapy includes 
immunosuppressants such as cyclosporin, corticosteroids and methotrexate which 
dampen the unrestrained immune response.  These medications do not exclusively 
target the immune system; the associated side effects are systemic and can limit the 
treatment regimen (88, 95, 114).  Biologics have more recently come into play, including 
use of interferons, TNF inhibitors, costimulatory molecule inhibitors and antibodies to 
deplete specific populations of immune cells.  CTLA-4 has shown promise as a target 
for autoimmunity, particularly in the case of rheumatoid arthritis (RA).  The costimulation 
modifier abatacept is a fusion protein containing the B7 binding domain of CTLA-4 
attached to the constant region fragment (Fc) of human IgG1 (91).  The Fc hinge was 
modified to eliminate Fc receptor recognition, which would reduce circulating drug 
levels.  Acting as a native CTLA-4 protein, this compound presumably binds to B7 and 
suppresses immune activation.  This therapy has proven effective in RA, even in 
patients who are refractory to other immune and biologic therapies, and is better 
tolerated than most alternatives (96).  A similar fusion protein, belatacept, substitutes 
two amino acids to favor a tighter interaction between B7 and CTLA-4, thus acting as a 
more potent inhibitor.  This compound has proven useful in transplant patients, where 
abatacept was less effective due to insufficient CD86 binding (43). 
 Tumor vaccination has been utilized in clinical trials for a variety of cancers (39).  
A potent adaptive T cell immune response subsequent to vaccination is necessary to 
attack and eradicate malignant cells; however, in many cases late stage patients have 
developed Treg populations that, in fact, protect the tumor.  Efforts to target Tregs using 
CD25-directed immunotoxins such as RFT5-SMPT-dgA have entered clinical trials, but 
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reduction is incomplete (90).  Instead by targeting CTLA-4, levels of immune response 
can be increased to help fight the tumor.  Fusion proteins with CTLA-4 joined to a tumor 
antigen of a B cell malignancy were examined in a mouse model in an effort to boost 
immune activity while simultaneously vaccinating against tumor cells (50).  The result of 
this study was an elevated antibody response, supporting CTLA-4 blockade as a 
valuable therapy. 
 Efforts to obstruct CTLA-4 function using antibodies in a mouse model resulted in 
tumor clearance and immunity to future tumor cell injections (59).  Since then, human 
antibodies to block CTLA-4 activity, particularly the FDA approved drug ipilimumab, 
have shown considerable success in clinical trials in conjunction with vaccines, 
chemotherapy and other treatments for metastatic melanoma and prostate cancer to 
revive the anti-tumor immune response (19, 25, 124).  While these efforts have shown 
promise, many patients experience severe adverse side effects including extensive 
autoimmunity.  Treatments that target CTLA-4 at the transcriptional level may improve 
efficacy while avoiding overstimulation of the immune response. 
 
Transcriptional regulation of CTLA-4.  Analysis of CTLA-4 induction has been limited.  
An early study found expression was limited to T cells and the first 335bp of the 
proximal promoter were necessary for maximum activation (87).  They also provide 
evidence that expression is regulated at the level of transcription.  A follow-up report 
found synergistic induction of CTLA-4 occurs with engagement of both the TCR and 
CD28, which can be blocked with either cyclosporin A or rapamycin (38).  In addition, 
mRNA stability is doubled when CD28 is activated together with the TCR.  Work by 
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Miller et al showed a correlation between reduced NFAT1 expression and reduced 
CTLA-4 (73).  Our previous work identified a bona fide NFAT1 binding site in the 
proximal promoter of CTLA-4 (41).  Upon stimulation of cells, NFAT1 binding is detected 
and histone acetylation occurs.  Through discovery of the mechanisms regulating 
transcription, we feel that distinctive pathways can be targeted to modulate CTLA-4 
expression for the novel treatment of autoimmunity and cancer. 
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MATERIALS AND METHODS 
 
Isolation of primary CD4 T cells and PBMCs: In brief, CD4 T cells were purified from 
Columbus Red Cross apheresis leukopacks from healthy donors. Cells were collected 
and incubated with 1.5 mL CD4 T cell Rosette Sep (Stem Cell Technologies) per 50 mL 
leukopack blood with rocking for 30 min.  Afterwards, cells were diluted with PBS, 
underlayered with Ficoll gradient, and separated by centrifugation at 1600 x g for 30 
min. The band of CD4s was isolated by aspiration and washed to remove the Ficoll. 
Residual RBC were lysed by resuspending the CD4 pellet with ACK lysis buffer (0.15 M 
NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA, pH 7.3) for 5 min. The CD4s were diluted in 
PBS, centrifuged at 1600 x g.  Final purities were >90% purity for all donors.  PBMCs 
were isolated using the Ficoll protocol as stated above.  Cells were maintained in RPMI 
1640 medium with 10% fetal bovine serum. 
 
Cell line culture: The E6-1 clone of Jurkat T cells were maintained at 105 to 2x106/mL 
in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. 
 
Biochemicals: All stimulations were with 50 ng/mL PMA and 1 g/mL A23187.  
Bortezomib (Millennium Pharmaceuticals) was reconstituted in water and maintained at 
a stock concentration of 2.5 mM.  ALLN and ALLM peptides (Sigma) were reconstituted 
in DMSO at stock concentrations of 10 mM.  MAPK inhibitors SB203580 and PD98059 
(Sigma) were maintained at stock concentrations of 10 mM in DMSO.  TPCA-1 was 
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reconstituted and stored at a stock of 10 mM in DMSO.  Curcumin and garcinol (Sigma) 
were stored as stock concentrations of 10 mM in DMSO.  Cyclosporin A (Sigma) was 
reconstituted at 10 mg/mL in 100% ethanol.  Camptothecin, SN-38 and etoposide 
(Sigma) were all reconstituted in DMSO at 10 mM stock concentrations.  All chemicals 
were stored at -20oC prior to use.  
 
RNA isolation: Total RNA was isolated from cells using TRIzol (Invitrogen) as 
recommended by the manufacturer.  Briefly, up to 107 cells were lysed in 1 mL TRIzol 
and incubated at room temperature for 5 min.  200 L chloroform was added followed 
by vigorous shaking for 15 s.  Samples were centrifuged for 15 min at 12 kRPM at 4oC 
and the aqueous layer was transferred to a new tube.  The RNA was precipitated by 
addition of 600 L isopropanol, thorough mixing and incubation at room temperature for 
10 min.  The RNA was pelleted by centrifugation at 12 kRPM at 4oC for 10 min followed 
by washing with 70% DEPC ethanol.  Samples were resuspended in 15 L DEPC water 
and heated to 55oC for 5 min prior to quantification by absorption at 260 and 280 nm. 
 
First strand cDNA synthesis: Reverse transcription was performed with up to 4 g 
total RNA.  Briefly, RNA was diluted to 10 L with DEPC water and combined with 1 L 
oligo dT (Invitrogen) and 1 L 10 mM dNTP mix (Invitrogen) and incubated at 70oC for 
10 min after which the samples were placed on ice.  A master mix of 4 L SuperScript II 
5x buffer, 2 L 0.1 M DTT and 1 L 50 mM MgCl2 per sample was made and 7 L was 
distributed to each sample.  Tubes were transferred to 42oC and 1 L SuperScript II 
reverse transcriptase was added.  After 1 h at 42oC the samples were transferred to 
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70oC for 15 min to deactivate the enzyme.  The volume was then increased to 50 L per 
g RNA initially added and samples were stored at -20oC until use. 
 
Quantitative real-time PCR (qPCR): Total RNA was isolated from cells using TRIzol 
as recommended by the manufacturer. Reverse transcription was performed with up to 
4 g total RNA to generate cDNA using SuperScript II reverse transcriptase (Invitrogen)  
and quantitative PCR was performed with the equivalent of 10 ng RNA per sample 
using an Applied Biosystems 7900HT set for 40 cycles at 95oC for 15 s, 60oC for 1 
min/cycle. Primers are listed in Table I and have similar amplification efficiencies. 
Analysis for relative gene expression was performed using the 2-CT method (67). The 
expression of each gene in each sample was performed in duplicates and the level was 
normalized relative to B2-microglobulin (B2M) for mRNA samples and input DNA for 
ChIP samples. 
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Gene Forward Reverse 
Actin TGCGTTGTTACAGGAAGTCCC CTATCACCTCCCCTGTGTGGA 
B2M TCTACTTTGAGTGCTGTCTCCATGT AAGTTGCCAGCCCTCCTAGAG 
CTLA-4 CTACCTGGGCATAGGCAACG CCCCGAACTAACTGCTGCAA 
FoxP3 ATCCGCCACAACCTGAGTCT GTCCACACAGCCCCCTTCT 
GAPDH CCCACTCCTCCACCTTTGAC CATACCAGGAAATGAGCTTGACAA 
GATA3 TCTGGAGGAGGAATGCCAAT CCGGGTTAAACGAGCTGTTC 
IFN- TCCTGTCACTGTCTCACTTAATCCTT TTAGGTTGGCTGCCTAGTTGG 
IL-2 GCAACCATTGTAGAATTTCTGAACAG CTGATATGTTTTAAGTGGGAAGCACT 
IL-4 CACAGGCACAAGCAGCTGAT CTCTGGTTGGCTTCCTTCACA 
NFAT1 TCCTGGAGATACCCTTGGAGC AGTCGATGGTTGCCCTCATG 
NFB p50 CAAATAGACGAGCTCCGAGACA GAGACTCGGTAAAGCTGAGTTTGC 
TNF- GGAGAAGGGTGACCGACTCA CTGCCCAGACTCGGCAA 
ChIP CTLA-4 GAGGACCCTTGTACTCCAGGAA CGAAAAGACAACCTCAAGCACTC 
ChIP CTLA-4 
Cotransfection GAGGACCCTTGTACTCCAGGAA AGATCGCAGATCTCGAGGGCT 
 
Table I.  PCR Primer Sets 
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Protein lysates: All lysis buffers were supplemented with protease inhibitor cocktail at 
1L/mL buffer immediately prior to use.  Whole cell total protein was prepared from 15 
million cells by resuspension of the cell pellet in 100L RIPA buffer (50 mM Tris pH 7.4, 
150 mM NaCl, 1% Triton X-100, 0.1% SDS).  Samples were briefly sonicated to shear 
genomic DNA and centrifuged to remove cellular debris.  Nuclear and cytosolic fractions 
were isolated by swelling cells in 100L Buffer A (10mM HEPES-KOH pH 7.9, 1.5mM 
MgCl2, 10mM KCl) for 15 min on ice followed by centrifugation at 6kRPM for 15 min at 
4oC.  Supernatant was removed and kept as the cytosolic fraction.  The nuclear pellet 
was then resuspended in 100L Buffer B (20mM HEPES-KOH pH 7.9, 1.5mM MgCl2, 
420mM NaCl, 0.2mM EDTA, 25% glycerol) and briefly sonicated to shear genomic 
DNA.  Both the nuclear and cytosolic fractions were then centrifuged to remove cellular 
debris.  All lysates were stored at -80C prior to use. 
 
Immunoblot analysis: Equal amounts of protein as indicated were denatured in 2x 
Laemelli buffer and boiled 5 min.  Proteins were separated by SDS-PAGE on 10% 
polyacrylamide gels.  Separated proteins were transferred to polyvinylidene difluoride 
membranes in transfer buffer (25 mM Tris base, 192.5 mM glycine, 15% methanol) 
overnight at 35 mA in 4oC with stirring.  The membrane was then blocked in I-Block 
(ABI) for 1 h at room temperature and incubated overnight at 4oC with one of the 
following primary antibodies: GATA3 (Abcam), phospho-GATA3 (Abcam), Actin (Santa 
Cruz), NFAT1 (Santa Cruz), FoxP3 (Abcam), polyubiquitin (Cell Signaling), IB (Cell 
Signaling), CTLA-4 (Beckman Coulter), histone 3 (Cell Signaling), phospho-MAPKAPK2 
(Cell Signaling) at 1:1000 dilution in I-Block.  The membrane was washed five times in 
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TTBS and the specific protein was detected with an appropriate secondary Ab (Santa 
Cruz) at 1:2000 dilution in I-Block for 1.5 h.  After washing in TTBS five times, protein 
bands were visualized by chemiluminescence autoradiography with either SuperSignal 
West Pico or Femto reagents (Pierce). 
 
20S proteasome assay: Cell lysates were prepared from 50x106 cells by resuspension 
in Proteasome Lysis Buffer (40 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton 
X-100 with addition of ATP to 2 mM immediately before use) and incubation on ice for 
30 min, briefly sonicated to shear genomic DNA and centrifuged to remove debris.  10 
g protein was diluted into a total of 40 L lysis buffer in an opaque 96 well plate.  After 
addition of 10 L 37.5 mM Suc-LLVY-AMC in DMSO (Enzo Life Sciences), reaction was 
incubated at room temperature and fluorescence was read every 5 min on a Thermo 
Fluroskan Ascent FL at an Excitation of 360 nm, Emission of 460 nm and gain of 85.  
Samples were analyzed in quadruplicate and normalized to substrate in lysis buffer 
without extract. 
 
Flow cytometric analysis: Cells were stained for extracellular expression of CD4 and 
CTLA-4 with 1 L antibody (Beckman Coulter IM2636U and BD 555853, respectively) 
per 106 cells for 20 min prior to washing with PBS and analysis on a FACS Calibur.  
Intracellular expression was measured by permeabilization and fixation with the FoxP3 
staining buffer set (eBioscience).  Briefly, 4x permeabilization/fixation concentrate was 
diluted to 1x with the provided diluent.  106 cells were resuspended in 1 mL 1x buffer 
and were incubated on ice 30 min.  Cells were centrifuged and washed 1x with PBS 
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followed by staining in 100 L PBS with 1 L PE-GATA3 (eBioscience 12-9966-42) or 1 
L PE-CTLA-4 (BD 555853) for 3 h.  Cells were washed three times with 100 L PBS, 
resuspended in 300 L PBS and analyzed on a FACS Calibur.  Data was analyzed with 
FlowJo software. 
 
Annexin V/PI staining for apoptosis: Staining buffer was diluted to 1x with ddH2O.  
105 cells were resuspended in 100 L 1x staining buffer with 1 L FITC-annexin V and 1 
L PI, then incubated 15 min at room temperature.  Cells were then diluted to 500 L 
with 1x staining buffer and transferred to 5 mL tubes followed by analysis by flow 
cytometry. 
 
Mixed lymphocyte reaction: Primary CD4 T cells were PMA/A23187 stimulated with 0, 
0.1 and 10 M bortezomib for 9 h and allogeneic PBMCs were fixed with 50 g/mL 
mytomycin C for 30 min.  Cells were then washed with PBS three times for 10 min each 
with rocking.  After counting, cells were plated in a 96-well flat bottom plate at 5x105 
PBMCs mixed with 5x105 CD4s per well.  Samples were treated with 0.5 g CTLA-4 
blocking antibody or mouse IgG2a control (Beckman Coulter IM2070 and A55763, 
respectively) and volumes were raised to 100 L per well with RPMI 1640 medium with 
10% fetal bovine serum.  After incubating 7 d, proliferation was measured by addition of 
20 L MTS reagent (Promega G5421), 3 h incubation at 37oC and measurement of 
absorbance at 570 nm on a Thermo MultiScan plate spectrophotometer. 
 
19 
 
 
Plasmids: CTLA-4 promoter constructs were cloned into the pGL3 luciferase vector as 
previously described (41).  The promoterless pGL3 Basic and SV40-driven pGL3 
Control were used as controls.  The GATA3 expression vector was kindly received from 
Dr. Gerd Blobel.  E1A 12S WT and mutant constructs were described previously (127). 
  
Reporter transcription analysis: Jurkat cells were seeded in 6 well plates at 1.5x106 
cells per sample in serum-free RPMI-1640.  1 g CTLA-4 380bp luciferase construct 
was transfected into each sample with increasing concentrations (0, 0.5, 1, 2 and 3 g) 
GATA3 expression vector or vector control plasmid using Lipofectin (Invitrogen) per 
manufacturer protocol in triplicate.  Cells were lysed in luciferase lysis buffer (25 mM 
glycylglycine, 15 mM MgSO4, 4 mM EGTA, 1% Triton X-100), with DTT added to 1 mM 
immediately prior to use, and equal protein concentrations were subjected to luciferase 
analysis.  The luciferase level was determined using a Lumat LB 9501 luminometer as 
described in Current Protocols in Molecular Biology (5). 
 
Chromatin immunoprecipitation (ChIP) assay: Cells were stimulated and treated as 
indicated, harvested and fixed for 10 min in 1% formaldehyde to crosslink protein and 
DNA complexes.  The reaction was quenched with addition of 1.25 M glycine for 5 min, 
cells were pelleted and resuspended in sonication RIPA buffer (50 mM Tris pH 7.4, 150 
mM NaCl, 1% NP-40, 1% SDS).  Samples were sonicated to shear DNA fragments to 
within 200-1000 bp, centrifuged to remove cellular debris and diluted 10-fold with ChIP 
dilution buffer to reduce SDS concentration.  Immunoprecipitations were performed 
using the ChIP Assay Kit (Millipore).  Briefly, after 1 h preclearing with protein A beads, 
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samples were treated with 10 g primary antibodies to GATA3 (Santa Cruz), NFAT1 
(Santa Cruz) or acetylated histone 3 K9/14 (Millipore) overnight at 4oC with rocking 
followed by addition of protein A beads for 1.5 h.  Samples were washed with Low Salt, 
High Salt, LiCl and TE buffer per manufacturer protocol.  After elution with NaHCO3 and 
SDS, protein crosslinks were reversed with 5 M NaCl at 65oC overnight.  
Immunoprecipitated DNA fragments were purified with QiaQuick gDNA columns 
(Qiagen) and evaluated by PCR or qPCR with primers specific to the CTLA-4 promoter 
as indicated in Table I. 
 
Agarose gel electrophoresis: PCR samples were stained with 10X xylene 
cyanol/bromophenol blue dye in 80% glycerol prior to loading onto 1% agarose 
Tris/Borate/EDTA (TBE) gels stained with 0.5 g/mL ethidium bromide.  Electrophoresis 
was run at 100V in TBE buffer and DNA fragment sizes were compared to the 1 kb Plus 
DNA Ladder (Invitrogen).  Gels were visualized by UV transillumination. 
 
Nucleic acid electroporation:  Primary CD4 T cells were electroporated at 107 cells 
per cuvette using the Amaxa system at a setting of U014.  Electroporation solution was 
82 L Nucleofector Solution with 18 L supplement (Amaxa Human T Cell Kit) for each 
sample.  Expression plasmids for GATA3 or control vector were electroporated at 2 
g/sample.  siRNA was electroporated at 20 pmol/sample SmartPool siRNA directed at 
GATA3 or off-target control (Dharmacon).  After electroporation, cells were transferred 
to RPMI 1640 culture media with 10% fetal bovine serum and allowed to rest 18 h.   
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Cell sorting: 40x106 bortezomib-treated and/or PMA/A23187 stimulated cells were 
stained with 20 L PE-CTLA-4 (BD 555853) in 1 mL PBS for 20 minutes at room 
temperature.  Samples were treated with 100 U/mL DNase (New England Biolabs), 
diluted to 10 mL PBS and passed through a cell strainer.  Cells were then sorted on a 
FACS Aria for presence or absence of surface CTLA-4 and checked for purity which 
exceeded 98% for all samples. 
 
Cytometric bead array (CBA): Cell culture supernatant was isolated from cell samples 
and frozen at -80oC prior to use.  The Th1/Th2 CBA kit (BD Biosciences) was used 
following manufacturer protocol.  Briefly, cytokine capture beads were reconstituted in 
Assay Diluent and combined with 50 L PE Detection Reagent and either 50 L culture 
supernatant or 50 L serially diluted standards (provided in the kit).  After incubation at 
room temperature for 3 h protected from light, samples were washed with 1 mL Wash 
Buffer.  Samples were resuspended in 300 L Wash Buffer and analyzed by flow 
cytometry using the provided template and cytometer setup beads.  The resulting data 
was analyzed with FCAP Array v 1.0.1 software (Soft Flow). 
 
Statistical analysis: Student’s t-test (2-tailed, unequal variance) was used to analyze 
the significance of differences between two experimental groups.  Data with a p value of 
0.05 or less were considered to be significant. 
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CHAPTER 1 
Altered Proteasome Function Leads to a GATA3-Dependent Increase in CTLA-4, a 
Mechanism That May Provide Insight to CTLA-4 Regulation in CTCL 
 
ABSTRACT 
 
The costimulatory molecule CTLA-4 functions as an immunomodulator generally 
associated with suppression of T cell proliferation.  Though structurally similar to CD28, 
which is expressed constitutively on T cells, transcription of CTLA-4 is highly regulated.  
CTLA-4 is elevated in cutaneous T cell lymphoma (CTCL), which may contribute to 
suppression of anti-tumor response during disease progression.  The transcriptional 
regulator GATA3 is also over-expressed in CTCL, but its significance in CTLA-4 is 
unclear.  We find that both transcript and protein levels of GATA3 are augmented by 
proteasome inhibition.  We show by polyubiquitin immunoblot that the proteasome 
pathway is dysregulated in CTCL.  Here we demonstrate a role for GATA3 in 
transcriptional regulation of CTLA-4 using the proteasome inhibitor bortezomib, a 
compound which reversibly binds to and inactivates the catalytic core of the proteasome 
through its boron atom. 
Bortezomib treatment leads to a dose-dependent increase in both GATA3 and 
CTLA-4 expression in normal CD4 T cells at both the transcript and protein level.  We 
also detect an increase in phospho-GATA3, the activated form, with bortezomib.  Flow 
cytometric analysis confirms the elevated CTLA-4 is properly trafficked to the cell 
surface.  Overexpression of GATA3 into Jurkat T cells by transfection stimulates a 
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CTLA-4 promoter luciferase construct.  The GATA3 expression can enhance CTLA-4 
promoter activity in a dose-dependent manner.  In primary CD4 cells, we detect specific 
binding of GATA3 to the CTLA-4 proximal promoter in bortezomib-treated CD4 cells by 
ChIP assay.  Furthermore, depletion of GATA3 with specific siRNA significantly impacts 
CTLA-4 transcription.  These results support a potential mechanism for increased 
CTLA-4 observed in CTCL T cells where GATA3 is increased.  Additionally, this work 
provides insight into potential effects on T cell function from proteasome inhibition with 
bortezomib.  As GATA3 supports differentiation of Th2 T cells, bortezomib may be 
useful in immune modulation in diseases associated with Th1 dominance and explain its 
effectiveness in graft versus host disease. 
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INTRODUCTION 
 
 Cutaneous T cell lymphoma (CTCL) is a malignancy of skin-homing CD4+ 
CD45RO+ T cells.  The leukemic form, Sezary Syndrome, is characterized by an influx 
of circulating tumor cells in the periphery.  An elevated level of CTLA-4 expression is 
detectable in tumor cells of patients with CTCL, which may contribute to immune 
suppression and tumor progression (126).  The mechanism contributing to the observed 
augmented CTLA-4 remains unclear.  We previously reported a functional NFAT1 
binding site in the CTLA-4 proximal promoter (41), but additional factors are likely 
involved in the complex regulation of this gene.  Reports have shown FoxP3 activates 
expression of CTLA-4 in Tregs (48), but whether FoxP3 plays a role in effector T cell 
expression is unknown.  CTLA-4 is also elevated when Th2-associated transcription 
factor GATA3 is overexpressed in a mouse model (115), but it is not clear whether the 
effect is causative.  Interestingly, GATA3 levels are also elevated in CTCL (78). 
 The 26S ubiquitin/proteasome pathway functions as a proficient cellular 
protein degradation system which enzymatically cleaves a variety of polypeptides (77).  
Substrates are marked for disposal by the successive addition of ubiquitin groups via a 
series of ligases.  Once a polyubiquitin tail is affixed, the protein is sent through the 19S 
cap and into the enzymatic 20S core where it is dismantled by a cylinder of proteases.  
The resulting peptides can either be metabolized, recycled into new proteins or loaded 
onto MHC I complexes for immune monitoring.  Proteasome inhibitors have shown 
increased cytotoxicity in certain malignancies, including multiple myeloma (117).  These 
compounds block this complex, resulting in stabilization of the substrates.  Specifically 
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in the case of T cell transcription factors, exogenous levels of NFAT1 have been 
reported to increase in the presence of proteasome inhibitors (130), though an 
additional study found the inhibitors diminished nuclear NFAT1 (14).  NFkB nuclear 
translocation requires cytosolic ubiquitination and degradation of IkB (86).  Blockade of 
proteasomal activity thus reduces NFkB activity.  Additionally, work by Yamashita et al 
shows proteasome inhibitors cause an increase in GATA3 protein (129).   
 This chapter investigates whether GATA3 is directly involved in CTLA-4 
transcription, particularly in the presence of proteasome inhibitors.  We examine 
whether the proteasome is dysfunctional in CTCL, which may explain why these cells 
exhibit increased GATA3.  Our findings show excessive levels of polyubiquitination in 
patient samples when compared to normal donors.  We then questioned whether 
proteasome inhibition alone can augment CTLA-4 expression in normal CD4 T cells.  
Not only do we find elevated CTLA-4 protein and transcript, but we show this increase is 
functionally able to suppress T cell proliferation.  Our findings also demonstrate an 
increase in activated GATA3, which binds to and induces CTLA-4 transcription.  Taken 
together, this work introduces a novel mechanism for CTLA-4 regulation. 
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RESULTS 
 
CTLA-4 and GATA3 are abnormally elevated in Sezary T cells.  To better 
understand the role of GATA3 in CTLA-4 regulation, we evaluated the level of CTLA-4 
and GATA3 transcript in Sezary Syndrome and normal peripheral CD4 T cells 
stimulated with PMA/A23187 from normal donors, Sezary patients and psoriasis 
patients.  Psoriasis samples serve as an inflammatory T cell-mediated disease control.  
The relative expression of CTLA-4 and GATA3 mRNA was analyzed by quantitative RT-
PCR (qPCR) as described in Materials and Methods.  Though resting T cells express 
minimal CTLA-4 mRNA, in Sezary T cells, the average level of CTLA-4 transcript is 
elevated 3.9-fold over normal in unstimulated samples (p=0.0069).  Upon induction, 
healthy donor CD4 cells exhibit a peak in CTLA-4 transcription after 2 hours, followed 
by a gradual decline in expression after longer stimulations.  In the Sezary samples 
analyzed, we detect significant increases in CTLA-4 expression at each of the time 
points as compared to normal donors (Figure1.1a).  Psoriasis samples are similar to 
normal, indicating its expression is specific to Sezary and not a consequence of the 
inflammatory response. 
Consistent with previously published data, we confirmed that GATA3 transcript is 
also significantly increased in these same Sezary patients (Figure1.1b).  Furthermore, 
we find GATA3 expression levels remain stable over the stimulation time course (p< 
0.005).  Immunoblot analysis of GATA3 levels in unstimulated whole-cell extract from 5 
Sezary patients confirms the elevated mRNA is translated into protein (Figure1.1c).  
Activation of GATA3 occurs after T cell stimulation and is dependent on phosphorylation 
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of serine 308 within the protein’s nuclear translocation region.  Using an antibody 
specific to phospho-GATA3, we find unstimulated Sezary cells exhibit an elevation in 
activated GATA3 despite lack of activation (Figure1.1c). 
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Figure 1.1.  CTLA-4 and GATA3 are augmented Sezary and normal T cells. a) PBMCs were isolated 
from Sezary patients (n = 6), psoriasis (n = 6) and normals (n = 6) and cells were stimulated with 
PMA/A23187 for the indicated time points.  Total RNA was isolated qPCR was performed as described in 
Materials and Methods with B2M serving as the internal control.  Results are shown as the average fold 
increase over unstimulated normal cells ± SEM (*p<0.05).  b) qPCR analysis of GATA3 expression in 
Sezary, psoriasis and normals using the same samples as in (a).  c) Immunoblot analysis of whole cell 
lysates from unstimulated normal donor (n = 2) CD4 T cells and Sezary (n = 5) patients.  PBMCs were 
purified and protein extracts were processed as described in Materials and Methods.  Samples were 
probed for expression of total GATA3 and phospho-GATA3 (p-GATA3) with specific antibodies as 
detailed in Materials and Methods.  Actin serves as a loading control. 
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NFAT and FoxP3 are not consistently abnormal in Sezary T cells.  We previously 
identified NFAT1 as an important transcription factor in CTLA-4 expression (41), and 
FoxP3 has also been identified as a factor involved in CTLA-4 regulation in Tregs (48, 
128).  Elevated FoxP3 levels were detected in Sezary (119), though another report 
failed to find an increase (42).  To determine whether either of these factors is 
responsible for the elevated CTLA-4 found in Sezary, we measured levels of mRNA and 
protein in our Sezary and normal samples.  There were no significant differences 
between normal donors and patients at the mRNA level (Figure1.2a, Fig1.2b), and 
protein expression was highly variable between patients (Figure1.2c).  Given the 
consistency of increased CTLA-4 in these samples, it is thus unlikely that NFAT1 or 
FoxP3 contribute significantly to the augmented CTLA-4 found in Sezary. 
 
Total polyubiquitin levels are elevated in Sezary T cells.  GATA3 has been shown to 
be regulated by the ubiquitin-proteasome pathway (129), but proteasome function has 
not been directly evaluated in Sezary.  To assess the proficiency of proteasome function 
in Sezary, we measured total ubiquitin from whole cell extracts of unstimulated cells by 
immunoblot and found increased total ubiquitin in Sezary cells compared to normals 
(Figure 1.3a).  The presence of excess ubiquitin in Sezary implies there may be 
dysregulation of the ubiquitin-26S proteasome pathway.  The 20S enzymatic region of 
the proteasome was assayed by cleavage of a Suc-LLVY-AMC fluorogenic peptide 
substrate.  We did not detect a significant difference between Sezary and normal 
extracts, though on average Sezary samples were better capable of degrading the 
peptide (Figure1.3b). 
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Figure 1.2.  NFAT1 and FoxP3 are sporadically dysregulated in Sezary and normal CD4 T cells.  
CD4 T cells were isolated from Sezary patients (n = 6) and normals (n = 6) and cells were stimulated with 
PMA/A23187 for the indicated time points.  Total RNA was isolated qPCR was performed as described in 
Materials and Methods with B2M serving as the internal control.  Results are shown as average fold 
increase over unstimulated normal cells ± SEM (* p<0.05).  qPCR expression analysis of a) NFAT1 and 
b) FoxP3 in Sezary and normals.  c) Immunoblot analysis of whole cell lysates from unstimulated normal 
donor (n = 2) CD4 T cells and Sezary (n = 5) patients.  CD4 T cells were purified and protein extracts 
were processed as described in Materials and Methods.  Samples were probed for expression of NFAT1 
and FoxP3 with specific antibodies as detailed in Materials and Methods.  Actin serves as a loading 
control. 
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Figure 1.3.  Proteasome activity analysis in normal and Sezary cells.  a) Immunoblot analysis of 
whole cell lysates from unstimulated normal donor (n = 2) CD4 T cells and Sezary (n = 5) patients.  
PBMCs were purified and protein extracts were processed as described in Materials and Methods.  
Samples were probed for total polyubiquitin with a specific antibody as detailed in Materials and Methods.  
Actin serves as a loading control.  b) 20S proteolytic core activity in Sezary cells and normals.  Cell 
lysates were assayed for 20S proteasome core activity by Suc-LLVY-AMC fluorogenic peptide cleavage.  
Emission measurements are normalized to background detection levels and are the averages of 5 normal 
and 5 Sezary CD4 samples ± SEM.  The proteasome activities were not significantly different (p>0.05). 
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Surface CTLA-4 expression increases in normal CD4 T cells treated with the 
proteasome inhibitor bortezomib.  Increased ubiquitin levels in Sezary cells suggest 
altered proteasomal regulation may play a role in enhancing CTLA-4 expression in 
Sezary.  We next study the regulation of CTLA-4 by blocking proteasome function in 
normal primary CD4 T cells using bortezomib, a dipeptide boronic acid inhibitor of the 
proteasome (1).  Normal CD4 T cells were stimulated with PMA/A23187 and treated 
with increasing concentrations of the specific proteasome inhibitor bortezomib and 
surface CTLA-4 was analyzed by flow cytometry.  Figure 1.4a shows a representative 
dot plot of CTLA-4 expression in bortezomib-treated (10 M) and untreated CD4 cells 
after 12 hours of stimulation.  Cells were stained with PE-conjugated anti-CTLA-4 and 
PC5-conjugated anti-CD4 prior to analysis.  The results demonstrate an overall increase 
in the quantity of CTLA-4-positive cells after proteasome inhibition, as well as an 
elevation in the magnitude of surface CTLA-4 expression on each cell.   
To understand the kinetics of surface CTLA-4 expression with proteasome 
inhibition, we conducted a stimulation time-course with treatments of 0, 0.1 and 10 M 
bortezomib in CD4 T cells from 4 healthy donors.  Untreated CD4 T cells exhibit a peak 
in percent CTLA-4 expression between stimulation times of 3 and 6 h, after which these 
levels progressively decline.  Treatment with bortezomib leads to sustained CTLA-4 
expression which remains stable through 12 h of stimulation (Figure1.4b).  Results are 
also presented graphically as percent CTLA-4 positive cells (Figure1.4c).  These data 
illustrate the potent effect of proteasome inhibition on CTLA-4. 
  
33 
 
 
 
 
Figure 1.4.  Proteasome inhibition augments CTLA-4 surface expression. a) Normal primary CD4 T 
cells were stimulated 12 h with PMA/A23187 and treated with and without 10  M bortezomib and 
analyzed for CTLA-4 expression. Cells were stained with PE -CTLA-4 and PerCP -CD4 and analyzed 
by flow cytometry as described in Materials and Methods.  Percentages represent double positive cells.  
The results are representative of at least 6 independent experiments.  b) CTLA-4 expression histogram of 
one normal donor treated with 0, 0.1 and 10 M bortezomib over a time course.  Cells were stimulated 
with PMA/A23187 for the indicated time points with and without the inhibitor and % CTLA-4 expression 
was determined by flow cytometry as described above. These results are representative of 4 independent 
experiments.  c) Graphical representation of average CTLA-4 surface expression ± SEM in (b) 
(**p<0.005). 
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Increased CTLA-4 in cells treated with bortezomib is not an artifact of apoptosis.  
As bortezomib has been used in treatment of multiple myeloma for its cytotoxic effects, 
we next sought to determine whether apoptosis plays a role in our system.  Primary 
CD4 T cells were treated with bortezomib and stimulated as in Figure 1.4 and analyzed 
by Annexin V/PI staining (Figure1.5).  Our results indicate an increase in apoptosis with 
stimulation alone.  Bortezomib treatment causes a modest increase in apoptosis after 9 
h, and only after 12 h at the 10 M concentration do we detect a significant increase 
over stimulation alone. 
 
CTLA-4 elevation with bortezomib suppresses T cell proliferation.  To determine 
whether the elevated CTLA-4 in bortezomib-treated cells can suppress T cell 
proliferation, we conducted a mixed lymphocyte reaction (MLR).  Purified primary CD4 T 
cells were stimulated for 9 h with 0, 0.1 and 10M bortezomib treatment, which resulted 
in 8.11%, 14.87% and 23.00% CTLA-4 expression, respectively.  Interestingly, CTLA-4 
expression diminishes within 12 h after washing in cells with stimulation alone, but at 
the 10 M concentration CTLA-4 remains detectable in 9.85% of cells in the 
bortezomib-treated population after 24 h and 4.49% after 48 h (Figure1.6a).  The cells 
were washed and then used in an MLR as described in Materials and Methods.  The 
bortezomib-treated cells effectively suppressed proliferation, which was reversed with 
CTLA-4 blocking antibody as compared to IgG control (Figure1.6b).   With the CTLA-4 
antibody, growth of 0.1 and 10 M bortezomib-treated cells improved by 51.1% and 
42.3%, respectively, while the stimulation alone samples did not significantly change. 
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Figure 1.5.  Apoptosis levels in normal CD4 T cells treated with bortezomib and stimulated with 
PMA/A23187.  1x10
6
 fresh CD4 T cells were treated with 0 (red), 0.1 (green) or 10 M (blue) bortezomib 
and stimulated for the indicated time periods.  Cells were then stained with annexin V and PI as detailed 
in Materials and Methods prior to analysis by flow cytometry.  Results are presented as histograms for 
intensity of annexin V staining and are representative of three independent experiments. 
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Figure 1.6.  Increased CTLA-4 with bortezomib treatment suppresses CD4 T cell proliferation.  
Primary CD4 T cells were isolated and treated with 0, 0.1 and 10 M bortezomib during PMA/A23187 
stimulation for 9 h.  Cells were washed 3x and returned to culture media without bortezomib or 
PMA/A23187.  a) CTLA-4 surface expression by flow cytometry over a time course after washing.  CTLA-
4 levels were measured at the indicated time points.  b) Proliferation was measured by mixed lymphocyte 
reaction.  Washed cells were plated at 5x10
4
/well of a 96-well plate and stimulated with an equal amount 
of mytomycin C-treated allogenic PBMCs as detailed in Materials and Methods.  Samples were 
supplemented with 0.5 g CTLA-4 blocking antibody or IgG control.  After 7 days, proliferation was 
measured by MTT assay as described in Materials and Methods.  Results are presented as the averages 
of quintuplicate samples ± SEM and are representative of three independent experiments (**p<0.005).  
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Bortezomib treatment leads to augmented mRNA expression.  We next sought to 
establish whether the responsible mechanism driving the CTLA-4 increase occurs at the 
level of transcription, protein regulation or surface trafficking.  To determine the effect of 
proteasome inhibition on mRNA expression of CTLA-4 and selected transcription 
factors, we treated fresh CD4 T cells from normal, healthy donors with bortezomib at 0, 
0.1 and 10 M.  Cells were treated with bortezomib and stimulated with a combination 
of PMA/A23187 in 3 h increments over 12 h.  Expression of mRNA was analyzed by 
quantitative real-time PCR as detailed in Materials and Methods. 
 The level of CTLA-4 transcript increases significantly with bortezomib treatment, 
particularly after extended stimulations (Figure1.7a).  Untreated samples follow a 
pattern where expression peaks at approximately 3 h of stimulation, after which it 
declines steadily over prolonged activation periods.  Cells treated with bortezomib, 
however, do not exhibit this same decline in CTLA-4 transcription after 3 h.  These cells 
instead maintain and continue to increase expression in a dose-dependent manner 
through 12 h of stimulation.  At the 12 h time point, treatment with 10 M bortezomib 
results in more than 7-fold greater CTLA-4 expression over untreated.  These results 
provide evidence that the observed effect of proteasome inhibition on CTLA-4 occurs 
upstream of CTLA-4 transcription, possibly through specific transcription factors. 
 We next investigated the relative mRNA transcript levels of NFAT1, FoxP3 and 
GATA3 in the presence of bortezomib.  Neither NFAT1 nor FoxP3 were significantly 
altered at the level of transcription (Figure1.7b, c).  Supporting previously published 
data, a dose-dependent increase of GATA3 mRNA was detected after proteasome 
inhibition (Figure1.7d).  Given that proteasome inhibition may lead to reduced 
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degradation of these factors and not necessarily an increase in transcript, mRNA 
analysis of these genes may not accurately reflect cellular protein levels. 
 
An alternate proteasome inhibitor, ALLN, also enhances CTLA-4 transcription.  In 
order to determine whether our results with bortezomib were due to proteasome 
inhibition and not an off-target effect of the drug, we utilized an alternative proteasome 
inhibitor, ALLN.  This chemical is a peptide aldehyde that inhibits both the proteasome 
and the calpain pathways.  As a control for calpain inhibition, we included the compound 
ALLM, which blocks calpain activity without suppressing proteasome function.  Cells 
were treated with 10 M ALLM, ALLN or bortezomib and stimulated for 9 h.  CTLA-4 
expression was measured by qPCR (Figure 1.8).  Both ALLN and bortezomib increased 
CTLA-4 transcription over vehicle control, while ALLM did not.   
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Figure 1.7. Transcript levels of CTLA-4, NFAT1, FoxP3 and GATA3 after bortezomib treatment.  
Expression of a) CTLA-4, b) NFATc2, c) FoxP3 and d) GATA3 mRNA in normal primary CD4 T cells 
treated with the indicated concentrations of bortezomib and stimulated with PMA/A23187 over a time 
course.  Normal CD4 T cells were purified using RosetteSep as described in materials methods.  Total 
RNA was isolated for qPCR analysis as previously described.  Results are the averages of 4 individual 
normal donors ± SEM analyzed by qPCR normalized to B2M and presented as the fold increase over 
unstimulated normal cells (*p<0.05, **p<0.005). 
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Figure 1.8.  CTLA-4 transcript also increases with proteasome inhibitor ALLN.  10x10
6
 primary CD4 
T cells were treated with 10 M ALLM, ALLN, bortezomib or an equivalent volume of DMSO followed by 
stimulation for 9 h.  Total RNA was isolated by Trizol preparation, cDNA was synthesized and qPCR was 
performed with primers specific to CTLA-4 as described in Materials and Methods.  Results were 
normalized to B2M and are presented as the averages of three independent experiments ± SEM 
(*p<0.05, **p<0.005).  
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Bortezomib-treated cells display transcription factor protein dysregulation.  To 
investigate whether proteasome inhibition leads to increased stability of transcription 
factors NFAT1, FoxP3 or GATA3, we probed whole-cell lysates from CD4 T cells 
collected from normal, healthy donors.  Cells were treated as they were for transcript 
studies in Figure 1.7.  Levels of IkB serve as a control to demonstrate proficiency of 
proteasome inhibition.  In parallel with flow cytometry data, bortezomib leads to 
maintained CTLA-4 expression over extended stimulations (Figure1.9).  NFAT1 protein 
was not elevated with bortezomib, indicating this transcription factor is not appreciably 
regulated by the proteasome pathway.  After longer stimulations at higher bortezomib 
concentrations, we instead detect a modest reduction in the intensity of NFAT1 protein.  
Untreated samples show enhanced FoxP3 expression over the stimulation time course, 
but expression is abrogated in cells treated with bortezomib.  As early as 6 h after 
stimulation, FoxP3 levels diminish with proteasome inhibition. 
 We find that GATA3 protein levels do not increase remarkably, however over 
longer stimulations with bortezomib we begin to distinguish a second, higher molecular 
weight band that may represent the phosphorylated, transcriptionally active species.  To 
investigate this further, we isolated nuclear and cytosolic fractions from cells stimulated 
for 6 h with treatments of 0, 0.1 and 10 M bortezomib.  By immunoblot we probed 
samples with an antibody specific for phospho-S308 GATA3 (Figure1.10a).  In the 
nuclear fraction, we detect a marked increase in activated GATA3 after bortezomib 
treatment.  Again, total GATA3 levels remain similar, but with proteasome inhibition the 
higher molecular weight band is more prevalent.  Cytosolic levels of total and phospho-
GATA3 remain comparatively lower in each sample.  As a method of determining the 
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purity of the fractionation, samples were also probed for total histone 3.  The cytosolic 
fractions do not contain any of this protein.  Interestingly, the 10 M nuclear sample 
shows elevated histone expression, indicating this protein may be regulated by the 
proteasome.  The included actin loading control verifies equal protein lysates were 
loaded in the gel. 
 We next quantified total GATA3 levels by permeabilization and staining with PE-
conjugated antibody for intracellular flow analysis (Figure1.10b).  Over the time course 
we find stimulation alone leads to a gradual, stepwise decrease in GATA3 expression 
from 72.44% in unstimulated cells to 28.73% after 12 h of stimulation.  Treatment with 
bortezomib results in stabilization of GATA3 expression across all time points at an 
average of 71.31% (+/- 3.55%) for 10 M samples.  
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Figure 1.9.  Transcription factor protein levels in bortezomib-treated CD4 T cells.  Immunoblot 
analysis of normal CD4 T cells stimulated in a time course with PMA/A23187 and treated with bortezomib 
for CTLA-4, GATA3, NFAT1 and FoxP3.  Whole CD4 T cell extracts were prepared with RIPA buffer and 
10 g total protein was separated on SDS-PAGE gels.  Proteins were transferred to PVDF membranes 
and probed with antibodies specific for IB (as a proteasome inhibition control), CTLA-4, GATA3, NFAT1 
and FoxP3 as described in Materials and Methods.  Actin serves as a loading control. Results are 
representative of 3 independent experiments.     
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Figure 1.10.  GATA3 protein is phosphorylated and stabilized with bortezomib.  a) Nuclear and 
cytosolic fractions were isolated from primary CD4 T cells treated with 0, 0.1 and 10 M bortezomib and 
stimulated for 6 h with PMA/A23187 as described in Materials and Methods. Lysates were probed with an 
antibody specific to phospho-GATA3 (S308) as described above.  b) Cells were treated and stimulated as 
in Figure 1.8, then permeabilized and stained with PE-conjugated antibody to GATA3 as described in 
Materials and Methods followed by flow cytometric analysis.  Percentages of GATA3 positive cells were 
determined by analysis with FlowJo software and are shown in red (0M), green (0.1M) and blue (10M) 
text for each time point.  Results from (a) and (b) are representative of three independent experiments.  
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Bortezomib activates the p38 kinase pathway, leading to GATA3 phosphorylation.  
We have shown that treatment with bortezomib causes a dose-dependent increase in 
the phosphorylated species of GATA3 protein (Figure 1.10a).  Previous work has 
implicated both the p38 and ERK pathway in GATA3 phosphorylation (70, 129).  To 
establish which mechanism is responsible in our system, we treated fresh primary CD4 
T cells with the p38-specific inhibitor SB203580 and the ERK inhibitor PD98059 in 
addition to bortezomib.  After stimulating 9 h, we measured IFN- (Figure 1.11a) and IL-
4 (Figure 1.11b) transcript levels to determine which kinase was more specific to 
GATA3.  IL-4 is heavily dependent on GATA3 activity whereas IFN- is not.  We find 
ERK inhibition suppresses both IFN- and IL-4 expression, which indicates this pathway 
may not be distinctly involved in GATA3 activation.  The p38 inhibitor selectively 
represses IL-4, supporting p38’s role in GATA3 regulation. 
 When we measure CTLA-4 transcript in these samples, we again find ERK 
inhibition blocks expression (Figure 1.11c).  The p38 inhibitor also suppresses CTLA-4 
activation, both with and without bortezomib (p<0.005).  We next examined phospho-
GATA3 protein levels with the p38 inhibitor by immunoblot (Figure 1.11d).  Bortezomib 
again increased GATA3 activation, but with the p38 inhibitor the level was reduced.  To 
verify the inhibitor adequately blocked p38 we probed these same samples with an 
antibody specific to phospho-MAPKAPK2, a direct downstream product of activated 
p38.  The resulting protein bands followed the same trend of phospho-GATA3, further 
supporting that the p38 pathway phosphorylates GATA3 in cells treated with 
bortezomib. 
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Figure 1.11.  The role of the p38 pathway in GATA3 and CTLA-4 expression in CD4 T cells after 
bortezomib treatment.  5x10
6
 primary CD4 cells were treated with 30 M p38 inhibitor SB203580, 30 M 
ERK inhibitor PD98059 or vehicle control for 1 h prior to stimulation with PMA/A23187 for 9 h.  Total 
mRNA was isolated and analyzed by qPCR as previously described with primers specific for a) IFN-, b) 
IL-4 and c) CTLA-4.  Results are presented as the averages of three independent experiments ± SEM 
(*p<0.05, **p<0.005).  d) Immunoblot analysis of stimulated primary CD4 T cells treated with 10 M 
bortezomib alone or with 30M p38 inhibitor SB203580 as compared to unstimulated and stimulated 
alone.  Cells were pretreated for 1 h followed by stimulation for 9 h with PMA/A23187.  Nuclear fractions 
were isolated as described previously and lysates were probed with antibodies specific to phospho-
GATA3 (S308) and phospho-MAPKAPK2 as an indicator of p38 activity.  Actin and histone 3 serve as 
loading controls and results are representative of three independent experiments. 
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The CTLA-4 promoter is augmented by GATA3.  The previous experiments 
demonstrate a correlation between GATA3 and CTLA-4 expression in normal CD4 T 
cells treated with bortezomib.  To address whether GATA3 can directly affect CTLA-4 
transcription, we cotransfected increasing concentrations of a GATA3 expression vector 
with pGL3 luciferase reporter plasmids containing regions of the CTLA-4 promoter into 
Jurkat T cells, which we previously demonstrated is dependent on an NFAT1 binding 
site (41).  GATA3 has been shown to directly interact with NFAT1, and addition of 
exogenous GATA3 leads to a dose-dependent increase in activity of a pGL3 construct 
with 380 bp of the CTLA-4 promoter by luciferase assay (Figure1.11).  The detected 
RLU values are significantly higher than co-transfections with the same quantity of 
control vector (p<0.005).  Similar results were obtained with a 1 kb CTLA-4 pGL3 
construct, as well (data not shown).  Importantly, co-transfection of GATA3 with the 
SV40 pGL3 control vector or a promoterless vector did not increase luciferase activity, 
indicating the effect is specific to the CTLA-4 promoter (data not shown).  These results 
provide evidence that GATA3 is able to augment CTLA-4 transcriptional activity. 
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Figure 1.12.  Ectopic GATA3 enhances CTLA-4 promoter activity.  A 380 bp CTLA-4 promoter 
luciferase construct (41) was cotransfected with increasing concentrations of GATA3 or vector control into 
Jurkat cells using Lipofectin as described in Materials and Methods.  Luciferase assay was performed 
and relative light units (RLU) were calculated.  Results are averages of three independent experiments ± 
SEM (**p<0.005). 
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GATA3 interacts with the endogenous CTLA-4 promoter in bortezomib-treated 
primary CD4 T cells.  To confirm the role of GATA3 at the endogenous CTLA-4 
promoter in primary cells, we performed chromatin immunoprecipitation assays (ChIP).  
Normal CD4 T cells were treated or untreated with 10 M bortezomib followed by 
stimulation for 6 h.  An unstimulated/untreated sample serves as a negative control.  By 
agarose gel analysis we detect binding of GATA3 to the CTLA-4 promoter in 
bortezomib-treated samples (Figure1.12a).  As a more sensitive method of analysis, we 
ran quantitative real-time PCR using the same samples and primer set (Figure1.12b).  
Results are interpreted as fold increase over isotype control, normalized to input 
samples, and are the averages of three independent experiments.  Upon stimulation we 
detect a 3-fold increase of GATA3 binding (p=0.028), however this interaction is 
markedly enhanced in the presence of bortezomib (p=0.043). 
 
Transient overexpression of GATA3 in CD4 T cells does not affect CTLA-4 
expression.  We next addressed whether addition of ectopic GATA3 alone would be 
sufficient to induce CTLA-4 to the same extent as proteasome inhibition.  Cells were 
electroporated with a GATA3 expression vector or LacZ control and stimulated for 9 h.  
We measured intracellular GATA3 (Figure 1.14a) to evaluate the efficacy of our 
expression vector and found that after 9 h stimulation there was a 17.2% increase from 
31.7% in the control LacZ sample to 48.9% with the GATA3 plasmid.  Importantly, the 
level of GATA3 detection in the LacZ population was consistent with what we found in 
non-electroporated cells in Figure 1.10b.  In these same samples, we next measured 
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extracellular CTLA-4 (Figure 1.14b).  We found no change in CTLA-4 expression with 
the addition of exogenous GATA3. 
 
GATA3 knockdown by siRNA reduces CTLA-4 transcript in bortezomib-treated 
CD4 T cells.  To further assess the role of GATA3 in CTLA-4 expression in bortezomib-
treated CD4 T cells, we knocked down GATA3 with siRNA.  Primary CD4 T cells were 
nucleoporated with a set of either GATA3 specific or control siRNA and allowed to rest 
for 18 h.  Samples were then stimulated in the presence or absence of 10 M 
bortezomib for 9 h, the point at which CTLA-4 expression becomes distinctly different 
with bortezomib treatment.  GATA3 expression was reduced by approximately 50% with 
targeted siRNA at both the mRNA and protein level (Figure 1.15 a, b).  As a GATA3-
dependent positive control, we measured IL-4 mRNA and found a reduction of 40.9% 
(p<0.05) by mRNA qPCR in an average of three independent experiments (Figure 
1.15c).  Expression of internal control GAPDH was not affected by GATA3-specific 
siRNA in these same samples (Figure 1.15d), indicating the transcript reduction was not 
a global effect.  Transcript levels of CTLA-4 in bortezomib-treated cells were diminished 
by 23.6% when GATA3 was depleted (p<0.05), but not with stimulation alone (Figure 
1.15d). 
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Figure 1.13.  GATA3 is detected at the endogenous CTLA-4 promoter with bortezomib.  1X10
6
 fresh 
CD4 T cells were stimulated and/or treated with 10 M bortezomib for 6 h as indicated, formaldehyde 
crosslinked and sheared by sonication.  ChIP was performed as described in Materials and Methods with 
antibodies to GATA3 and an isotype control.  Crosslinks were reversed and the DNA was purified for 
amplification with primers spanning the CTLA-4 promoter.  Input samples serve as a loading control.  a) 
Agarose gel of PCR products.  b) Quantification by qPCR with primers spanning the proximal promoter 
where samples are normalized to isotype control and presented as the fold over unstimulated/untreated.  
Presented results are the average of three experiments ± SEM (*p<0.05). 
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Figure 1.14.  Ectopic GATA3 does not transiently affect CTLA-4 expression.  10x10
6
 primary CD4 T 
cells were electroporated with 2 g GATA3 or LacZ expression vectors using the Amaxa system as 
described in Materials and Methods.  Cells were cultured 18 h prior to stimulation for 9 h.  a) Intracellular 
GATA3 levels were determined by permeabilization of cells and staining with a PE-conjugated GATA3 
antibody as described in Materials and Methods followed by flow cytometric analysis.  Histograms were 
generated with FlowJo software.  Percentages of GATA3 expression are shown in green (LacZ) and red 
(GATA3) text.  b) Extracellular CTLA-4 was measured by staining with a PE-conjugated CTLA-4 antibody 
and analysis by flow cytometry.  Results are representative of three independent experiments.   
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Figure 1.15.  GATA3 knockdown by siRNA reduces CTLA-4 mRNA in bortezomib-treated CD4 T 
cells.  Using the Amaxa system, 10X10
6
 fresh CD4 T cells were electroporated with 20 pmol control or 
GATA3-targeted SMARTpool siRNA (Dharmacon).  Cells were rested for 18 h then stimulated 9 h with 
and without 10 M bortezomib. Analysis of GATA3 a) protein and b) transcript was conducted by 
intracellular flow and qPCR, respectively.  Levels of c) IL-4, d) GAPDH and e) CTLA-4 mRNA were 
measured by qPCR. Results are presented as averages of three independent experiments ± SEM 
(*p<0.05). 
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Elevated GATA3 transcript in bortezomib-treated CD4 T cells does not guarantee 
surface CTLA-4 expression.  To establish whether the cells expressing CTLA-4 also 
have enhanced GATA3 transcript, we sorted bortezomib-treated and untreated cells for 
surface CTLA-4 and evaluated their mRNA profile by qPCR (Figure 1.16).  Cells were 
separated into CTLA-4 + and – fractions to a purity greater than 98%.  As expected, 
CTLA-4 mRNA expression is higher in the CTLA-4+ population (Figure 1.16a), and 
bortezomib treatment nearly doubles what is detected with stimulation alone.  
Surprisingly, GATA3 expression, though elevated with bortezomib, is not significantly 
different in the CTLA-4+ fraction (Figure 1.16b).  We find NFAT1 levels are increased in 
the CTLA-4+ population and as we have observed previously bortezomib does not 
impact NFAT1 expression (Figure 1.16c).  FoxP3 is also higher in cells expressing 
CTLA-4, and there is a modest decrease in the presence of bortezomib (Figure 1.16d). 
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Figure 1.16.  Expression profile in cells sorted for surface CTLA-4.  40x10
6
 CD4 T cells were 
stimulated 9 h with either 10 M bortezomib or no treatment followed by staining with PE-conjugated -
CTLA-4 and sorting for CTLA-4 + or – fractions.  After isolation of mRNA, expression of a) CTLA-4, b) 
GATA3, c) NFAT1 and d) FoxP3 were measured by qPCR as previously described.  Presented results 
are the averages of three independent experiments ± SEM. 
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NFB does not inhibit CTLA-4 transcription.  Proteasome inhibition blocks IB 
dissociation from NFB, and thus inhibits NFB’s activity as a transcription factor.  As 
NFB can function as a transcriptional repressor (16), we next wanted to evaluate 
whether NFB can block CTLA-4 activation.  This could contribute to the CTLA-4 
enhancement we find in cells treated with bortezomib.  By inhibiting NFB directly with 
the compound TPCA-1 followed by 9 h stimulation, we are able to examine whether 
NFB blockade results in increased CTLA-4 transcription (Figure 1.17).  To verify NFB 
is effectively repressed, we measured transcription of the NFB-dependent gene TNF- 
by qPCR (Figure 1.17a).  We find TPCA-1 reduces expression dose-dependently, with 
significant decreases after 1 and 10 M treatments.  CTLA-4 expression is not affected 
by TPCA-1 treatment (Figure 1.17b).  We include samples treated with bortezomib for 
comparison, which do exhibit elevated CTLA-4. 
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Figure 1.17.  NFB inhibitor TPCA-1 does not affect CTLA-4 expression.  5x10
6
 primary CD4 T cells 
were treated with the indicated concentrations of TPCA-1 and stimulated for 9 h followed by mRNA 
analysis of a) TNF (as an NFB-dependent gene control) and b) CTLA-4 by qPCR as previously 
described (*p<0.05).  Effect of 0.1 and 10 M bortezomib is shown as red bars in panel (b) for 
comparison.  Results are the averages of three independent experiments ± SEM. 
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DISCUSSION 
 
 Expression of CTLA-4 is elevated in tumor cells of patients with cutaneous T cell 
lymphoma (126), which may contribute to decreased anti-tumor immunity in later stages 
of the disease.  The mechanism governing the observed transcriptional dysregulation 
has not been well characterized.  In this study we show excessive polyubiquitination of 
proteins in the malignant cells of CTCL, which implies the ubiquitin-mediated 
proteasome pathway is defective.  These results correlate with elevated CTLA-4 and 
GATA3 protein and transcript in patient samples, but a link between proteasome activity 
and expression of these genes had not been previously explored.  By treating healthy 
primary CD4 T cells with bortezomib, we are able to isolate the single element of 
proteasome deficiency and establish a role for this pathway in CTLA-4 regulation.  Our 
results not only demonstrate a novel T cell response to bortezomib, but also identify a 
direct role for GATA3 in CTLA-4 transcription.  We show GATA3 protein levels are 
stabilized by proteasome inhibition and we also observe a dose-dependent increase in 
phosphorylation at S308, the transcriptionally active form.  By luciferase and ChIP, we 
find GATA3 is able to bind to and induce the CTLA-4 promoter, and bortezomib 
enhances this interaction.  After siRNA suppression of GATA3, CTLA-4 induction with 
bortezomib is significantly reduced.  Taken together, these data delineate a mechanism 
where proteasome inhibition increases CTLA-4 expression through stabilization and 
activation of GATA3. 
This study reveals aberrant proteasome regulation in CTCL, as detected by total 
polyubiquitin immunoblot.  Interestingly, when we assayed the 20S proteolytic core 
59 
 
 
subunit of Sezary and normal extracts we found it was moderately, though not 
statistically significantly, more active in patient samples.  This is not entirely unexpected 
given gene array analysis has identified two 26S proteasome regulators, PSMD3 and 
PSMC5 which are upregulated in Sezary (21).  Taken together these data indicate the 
profuse polyubiquitination detected in Sezary may be due to impaired function of 
another component within the ubiquitin-proteasome pathway aside from the 20S 
proteolytic core.  Given that a multitude of proteins interact with and direct the function 
of this pathway (45), further analysis will be required to identify the exact cause.   
By inhibiting the proteasome in primary CD4 cells with either bortezomib or 
ALLN, we show this defect alone can augment CTLA-4 expression.  When stimulating 
with PMA/A23187, we find CTLA-4 transcript levels are rapidly induced but peak at 3 h, 
after which they steadily decline (Figure 1.7a).  Addition of bortezomib prevents this 
regression, allowing expression levels to remain elevated through 12 h.  Interestingly, 
both GATA3 and CTLA-4 follow a similar kinetic trend when CD4 T cells are stimulated 
in the presence and absence of the proteasome inhibitor.  Our data shows GATA3 is 
also stabilized in the presence of bortezomib, which substantiates previous studies with 
alternative proteasome inhibitors (129).  Aptly, GATA3 is also overexpressed in CTCL, 
but further studies will be required to determine whether this is due to proteasome 
dysregulation.  In normal CD4 T cells with stimulation alone, GATA3 protein levels 
diminish over time (Figure 1.19b).  Bortezomib treatment leads to sustained GATA3 
expression, which in turn increases transcription of GATA3-dependent genes.  CTLA-4 
has been implicated as a Th2-associated gene (83), which is further supported here 
where we show a direct involvement of GATA3 in CTLA-4 transcription. 
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We were initially concerned that the effects we had observed were a 
consequence of cytotoxicity from proteasome inhibition.  In addition to multiple 
myeloma, bortezomib has been tested in a variety of other hematological malignancies 
(46, 47, 85) as well as solid tumors (3, 89, 118, 125) for its ability to induce apoptosis.  
Only when cells were treated for 12 h at the 10 M concentration in our system did we 
detect elevated annexin V staining.  Generally stimulation alone caused a slight amount 
of cell death, likely due to PMA toxicity.  The effect of bortezomib on CTLA-4 is evident 
after 6 to 9 h, time points at which apoptosis levels are minimal.  These data indicate 
the observed increase in CTLA-4 is independent of apoptosis induction. 
As CTLA-4 is involved in downregulation of T cell proliferation, we wanted to 
address whether the increased CTLA-4 in cells treated with bortezomib could 
functionally suppress growth.  Long treatments with bortezomib will induce apoptosis, 
but since bortezomib is a reversible proteasome inhibitor we are able to vastly reduce 
the concentration of the compound in the cell culture media by washing.  Once the 
bortezomib and stimulation are removed, CTLA-4 levels begin to decline.  However, we 
found bortezomib-treated cells sustained surface expression over longer intervals.  Our 
mixed lymphocyte reaction showed increased suppression with bortezomib 
pretreatment.  We can determine CTLA-4 is responsible for the observed growth 
suppression by blocking its activity with a specific antibody.  These results identify 
bortezomib as a T cell growth inhibitor through a mechanism independent of apoptosis, 
which may in part explain the protective effects of this drug in prevention of GVHD 
without sacrificing anti-tumor effects (107). 
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Our results introduce a novel mechanism for CTLA-4 transcriptional regulation 
where GATA3 interacts with the proximal promoter.  GATA3 was loosely connected to 
CTLA-4 by van Hamburg et al (115) with their use of a GATA3 overexpressing mouse 
model, and our data show a direct role for this transcription factor.  In our luciferase 
study GATA3 augmented promoter activity with as little as 380 bp which indicates 
GATA3 may be involved with the proximal promoter.  Our ChIP assay results support 
this, as primers were designed for the NFAT1 binding region.  Alignment software 
predicts three potential GATA3 binding sites within the proximal promoter.  We were 
unable to detect GATA3 binding to these sequences by electrophoretic mobility shift 
assay, however GATA3 may not be directly in contact with the DNA.  Indeed, previous 
studies have shown GATA3 works cooperatively with NFAT1 to activate Th2 cytokines 
(6), and coprecipitation in cells transfected with expression constructs shows these two 
proteins can physically interact (57) which may be the case for CTLA-4 regulation.  Our 
efforts to coprecipitate endogenous proteins were unsuccessful, but this may have been 
due to low protein concentrations. 
 FoxP3 was also shown to cooperate with NFAT1 to regulate CTLA-4 in the 
context of regulatory T cells (128), which express CTLA-4 constitutively.  This chapter 
has focused on induced CTLA-4 expression in effector CD4 T cells.  Our data does not 
support a mechanism of FoxP3 involvement in increasing CTLA-4 by proteasome 
inhibition.  Indeed, in the presence of bortezomib FoxP3 levels are suppressed as early 
as 6 h after treatment and stimulation (Figure 1.8).  As FoxP3 is a reliable marker of 
Treg cells, this would support that proteasome inhibition does not induce a transition to 
the Treg phenotype.  In fact, it has been reported that GATA3 can directly bind to the 
62 
 
 
FoxP3 promoter and suppress FoxP3 transcription (71).  We also assayed our whole 
cell extracts for FoxP3 expression by immunoblot and found that only 2 of 5 Sezary 
patients had expression levels higher than normal.  This is consistent with previous 
findings showing erratic expression of FoxP3 in CTCL (42, 119). 
 Our previous work did not identify a role for NFB in activation of CTLA-4.  If 
NFB was required for CTLA-4 transcription, proteasome inhibition would suppress 
expression.  We also wanted to determine if NFB plays a suppressive role in CTLA-4, 
and through use of specific inhibitor TPCA-1 we again find NFB has no effect.  Not 
only does this provide more details to CTLA-4 regulation, but it also suggests 
therapeutic use of NFB inhibitors should not directly modulate CTLA-4 expression. 
 When we sorted cells to isolate those with surface CTLA-4 expression, we found 
mRNA levels of CTLA-4 were roughly 10-fold higher in cells that were CTLA-4+, 
regardless whether they were treated with bortezomib.  This implies a certain subset of 
CD4 T cells may be more likely to express CTLA-4.  Interestingly, cells treated with 
bortezomib had about 2-fold higher mRNA and surface protein which suggests 
trafficking to the cell membrane also increases in this population.  Expression of NFAT1 
was nearly equivalent among all samples tested, but FoxP3 was specifically expressed 
in CTLA-4+ cells.  A slight but not statistically significant reduction in FoxP3 mRNA was 
detected in bortezomib-treated cells as compared to stimulation alone, which mimics 
what we observe at the protein level.  We were surprised to find GATA3 levels were not 
significantly higher in the CTLA-4+ fraction, particularly in the bortezomib-treated 
samples.  This may indicate either another factor is involved or that activation of GATA3 
only occurs in a limited collection of cells.  
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 GATA3 activation plays a critical role in bortezomib-induced CTLA-4 expression.  
We show the p38 kinase pathway mediates GATA3 phosphorylation in the presence of 
bortezomib.  This is not unexpected, given proteasome inhibition triggers a stress 
response and p38 is activated by cell stress conditions (92).  The inhibitor we used, 
SB203580 did not completely inactivate p38 in our cells, as illustrated by the phospho-
MAPKAPK2 blot with our samples.  Importantly, the level of phospho-MAPKAPK2 
reduction did coincide with that of phospho-GATA3.  We did not detect an increase in 
CTLA-4 upon transient overexpression of GATA3, but this may have been due to a lack 
of GATA3 phosphorylation under these circumstances.  Overexpression in a mouse 
model did, however, result in CTLA-4 upregulation (115).   
 Our targeted inhibition of GATA3 by siRNA led to greater than a 50% reduction in 
GATA3 mRNA and protein.  Similar to our other experiments, bortezomib treatment and 
stimulation for 9 h increased GATA3 roughly 2.5-fold over unstimulated cells when 
electroporated with control siRNA.  GATA3-directed siRNA suppresses mRNA levels in 
bortezomib-treated samples to just below that of the unstimulated control.  This was a 
functionally adequate reduction, as observed in the measured effect on the GATA3-
dependent Th2 cytokine IL-4.  The statistically significant reduction in CTLA-4 after 
GATA3 ablation again validates the important role GATA3 plays in CTLA-4 activation in 
cells treated with bortezomib.    Proteasome inhibition likely triggers the kinase pathway 
responsible for GATA3 activation as well, as the level of phospho-GATA3 increases 
dose-dependently with bortezomib.  Taken together, these data show that both 
stabilization of GATA3 protein and increased phosphorylation are essential for the 
observed augmentation of CTLA-4 transcription.  
64 
 
 
CHAPTER 2 
Identification of the Role of p300 in Activation of T-cell Regulator CTLA-4 by Use 
of Adenovirus 2 E1A 
 
ABSTRACT 
 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an important regulator 
of T cell activation, and thus transcriptional regulation is a tightly controlled process.  
Expression of the CTLA-4 gene in effector T cells is induced by activation and binding of 
NFAT1 in the proximal promoter. Upon activation, histones in the CTLA-4 proximal 
promoter become acetylated at lysines 9 and 14.  The presence of these modifications 
is conventionally recognized as an activated chromatin region.  As NFAT1 has no 
known histone acetyltransferase (HAT) activity, we sought to determine whether a 
cofactor may be involved by utilizing adenovirus 2 E1A proteins.   
Adenovirus 2 E1A 12S contains two distinct conserved regions.  The E1A 
conserved region 1 (CR1) and 2 (CR2) interact with a variety of cellular proteins 
including histone acetyltransferase p300 and cell cycle regulator pRb, respectively.  By 
co-transfecting luciferase CTLA-4 constructs with wild-type and mutant E1A 12S 
plasmids in the leukemia cell line Jurkat, we show that the CR1 region, but not CR2, is 
capable of inhibiting CTLA-4 transcription.  During normal activation of this gene, 
acetylation of histone 3 occurs at lysines 9 and 14.  Analysis utilizing chromatin 
immunoprecipitation (ChIP) assays reveals that this histone acetylation does not occur 
in the presence of the E1A 12S CR1 region, implicating the potential involvement of 
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p300.  Using the p300 inhibitors curcumin and garcinol, we are able to block 
transcription of CTLA-4 and demonstrate a role for p300 in CTLA-4 activation.  Through 
use of calcineurin inhibitor cyclosporin A (CyA), we also show NFAT1 binding to the 
proximal promoter precedes histone acetylation by ChIP assay. 
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INTRODUCTION 
 
 Gene regulation involves the concerted activity of transcription factors and 
epigenetic modifiers to either initiate or suppress expression.  Organization and 
packaging of genomic DNA is a dynamic process maintained by the wrapping of DNA 
around nucleosomes made up of core histone proteins H2A, H2B, H3 and H4 (68).  A 
variety of covalent modifications to specific residues of these proteins can further 
remodel DNA/histone complexes into open, active regions of euchromatin or 
compressed, transcriptionally inaccessible heterochromatin (54).  Specifically, histone 3 
acetylation at lysine residues 9 and 14 has been associated with elevated gene 
expression (2).  Addition and removal of acetyl groups at these sites is controlled by the 
balance between histone acetyltransferases (HATs) or deacetylases (HDACs), 
respectively (106).   
The acetyltransferase p300 was initially identified due to its interaction with the 
adenovirus early protein E1A (36).  Since then, p300’s role as a transactivator and HAT 
has been elucidated.  Previous reports have shown p300 interacts with an assortment 
of transcription factors, including but not limited to AP-1, p53, STAT family members, 
TFIIB, NFB, NFAT1 and members of the GATA family, among many others (34).  
Structurally homologous to p300, CREB-binding protein (CBP) also cooperates with 
many transcription factors and acetylates many cellular proteins including histones, 
which leads to the restructuring of chromatin for gene expression.  The CBP and p300 
proteins are often paired together and can be referred to collectively as p300/CBP.  
Another related cofactor, p300/CBP-associated factor, or PCAF, associates with p300 
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and CBP to fulfill its function as a cofactor.  Through use of a series of E1A mutants, Liu 
et al established a role for p300 in IL-5 regulation (65) and we employed a similar 
technique to study CTLA-4 transcription. 
More recently, chemical inhibitors to HATs have been discovered and exploited 
for their impact on gene transcription.  The polyphenolic compound curcumin efficiently 
disrupts p300-dependent histone acetylation without affecting PCAF (8).  Less 
specifically, polyisoprenylated benzophenone, or garcinol, can also block p300 but has 
a stronger potency toward PCAF (7).  The high cellular toxicity of garcinol led to 
development of its derivative LTK-14, which is specific to p300 but is currently not 
commercially available.  The effect of these compounds on CTLA-4 transcription has 
not previously been investigated. 
Our initial studies identified an NFAT1 binding site in the proximal CTLA-4 
promoter in addition to histone acetylation upon T cell induction (41).  The main 
objective of this section was to determine whether p300 is responsible for the detected 
acetylation at the CTLA-4 promoter through use of a panel of E1A constructs in addition 
to the above described chemical inhibitors to p300.   
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RESULTS 
 
The CR1 region of the E1A 12S protein suppresses activity of CTLA-4 reporter 
constructs.  To determine whether E1A proteins can impact CTLA-4 expression, wild-
type and mutant 12S E1A vectors were cotransfected with a series of CTLA-4 luciferase 
promoter constructs in Jurkat T cells as detailed in the schematic in Figure 2.1.  The two 
E1A mutants individually eliminate the two conserved regions (CR), CR1 and CR2 of 
the wild-type 12S splice variant.  CR1 has been shown to sequester cellular proteins 
including p300, while CR2 is known to bind pRB.  For this study, we utilized one 264 bp 
CTLA-4 promoter construct that omitted the NFAT1 binding site and three constructs 
with larger promoter regions of 380 bp, 4 kbp and 6 kbp.   
After cotransfection, we measured promoter activity by luciferase assay as 
described in Materials and Methods (Figure 2.2).  Our results are presented as relative 
light units (RLU).  As expected due to the lack of NFAT1 binding, the 264 bp construct 
had undetectable luciferase levels which were unaffected by the presence of E1A 
vectors.  For the remaining constructs we find strong luciferase activity for the promoter 
alone, but the addition of wild-type 12S E1A significantly suppresses promoter 
induction.  Mutation of the CR1 region, which is known to bind p300, results in the 
rescue of luciferase activity for each of our promoters.  In the 4 kbp and 6 kbp 
constructs, we actually detect an increase in RLUs with this mutant.  However when the 
CR2 region is mutated, luciferase activity is not recovered. 
  
69 
 
 
 
 
Figure 2.1. CTLA-4 promoter constructs and 12S E1A mutants. a) The CTLA-4 promoter was cloned 
from genomic DNA and 5’ deletion constructs were ligated into luciferase reporter plasmid pGL3.  This 
study used clones of 264 bp, 380 bp, 4 kbp and 6 kbp.  As indicated in the top of the schematic, previous 
work has shown NFAT1 binds to the -280 region of the CTLA-4 promoter. b) Schematic of 12S E1A wild-
type and mutants CR1 and CR2.  The CR1 region binds p300/CBP while CR2 binds pRB. 
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Figure 2.2. CTLA-4 promoter activity with E1A wild-type and mutant plasmids. Jurkat cells were 
cotransfected with 2 g each E1A plasmid and in combination with 2 g CTLA-4 luciferase constructs 
using Lipofectin as detailed in Materials and Methods.  Results are presented as the average RLU of 
triplicate samples and are representative of three or more independent experiments ± SEM (* p<0.05). 
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Histone acetylation is blocked by wild-type 12S E1A but not CR1.  To determine 
the cause of promoter activity suppression in cotransfected samples, we conducted 
chromatin immunoprecipitation (ChIP) assays to measure levels of NFAT1 binding and 
histone 3 acetylation (Figure2.3).  After Jurkat cotransfection of E1A plasmids with the 4 
kbp CTLA-4 luciferase construct as in Figure 2.2, samples were either stimulated with 
PMA/A23187 for 4 h or left unstimulated.  Chromatin was prepared as described in 
Materials and Methods and immunoprecipitated with antibodies specific to NFAT1 and 
acetyl histone 3 at lysines 9 and 14.  The resulting DNA was analyzed by real-time PCR 
with a forward primer specific to the CTLA-4 promoter and a reverse primer within the 
luciferase gene of pGL3.  As Jurkat cells do not express CTLA-4, this primer set allowed 
us to eliminate background detection of the endogenous promoter. 
 After stimulation, we detect an increase in NFAT1 binding at the transfected 
promoter (Figure2.3a).  The 2- to 3-fold increase after stimulation is similar to what we 
previously reported at the CTLA-4 promoter in stimulated PBMCs, indicating the 
exogenous promoter behaves in a similar manner to what we find in primary cells.  
Addition of the 12S E1A wild-type and mutant plasmids does not reduce NFAT1 binding 
at the exogenous promoter.  In fact, addition of the wild-type 12S E1A construct results 
in elevated detection of NFAT1. 
 Histone acetylation is also enhanced after stimulation, though the degree of 
increase is much lower than that of NFAT1 (Figure2.3b).  Wild-type 12S E1A blocks 
histone acetylation, reducing detectable levels to 25% of the non-E1A samples.  
Interestingly, there is an equivalent reduction in the unstimulated cells, which implies 
acetylated histones accumulate on the plasmid in the absence of activation.  When the 
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E1A CR1 region is eliminated, histone acetylation is no longer inhibited.  Similar to the 
luciferase results in Figure 2.2, our CR2 mutant impedes acetylation to levels 
comparable to wild-type. 
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Figure 2.3. ChIP assay analysis of cotransfected Jurkat cells. Jurkat cells were transfected with 2 g 
4 kbp CTLA-4 luciferase plasmid and 2 g E1A constructs using Lipofectin as described in Materials and 
Methods.  Cells were formaldehyde crosslinked and sheared by sonication.  ChIP was performed as 
described in Materials and Methods with antibodies to a) NFAT1, b) acetylated histone 3 (K9/14) and 
isotype control.  Crosslinks were reversed and the DNA was purified for amplification with primers 
spanning the NFAT binding region at -280 bp through the 5’ region of the luciferase gene.  Results are 
presented as the average fold over unstimulated without E1A normalized to isotype control and are 
representative of two independent experiments ± SEM (* p<0.05). 
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The E1A 12S construct suppresses CTLA-4 transcription in primary CD4 cells.  
The previous experiments show our E1A wild-type and mutant constructs can impact an 
ectopic CTLA-4 promoter in the Jurkat cotransfection system, but our objective is to 
study the endogenous CTLA-4 promoter.  We next transfected E1A into normal primary 
CD4 T cells to observe the effect on CTLA-4 expression.  Using the Amaxa nucleofector 
system, 2 g each E1A vector or control plasmid was electroporated into freshly 
isolated CD4 cells.  After resting 36 h, cells were stimulated 4 h, the point at which 
CTLA-4 expression is at its peak.  By real-time PCR we then measured induction of 
CTLA-4 as compared to unstimulated control plasmid in each of the samples (Figure 
2.4a).  Similar to our findings with the luciferase assay, we detect a 52.9% reduction of 
CTLA-4 transcription with wild-type 12S E1A.  It is important to note the level of 
suppression in these experiments is limited to the transfection efficiency, which ranges 
from 40-60% in these samples by eGFP transfection.  When the p300-binding CR1 
region is mutated, CTLA-4 expression is recovered.  Contrary to the luciferase results, 
we also find expression is restored with the CR2 mutant. 
 As the goal of these studies is to find methods to specifically target CTLA-4 
expression, we also utilized these samples to measure expression of IL-2 (Figure 2.4b) 
and GAPDH (Figure 2.4c).  We find IL-2 levels are also reduced, by 71.3%, with the 
12S construct, indicating the effect is not specific to CTLA-4.  The repressive effect of 
the 12S construct is not global, however.  Expression of internal control gene GAPDH is 
unaffected by this vector, implying the effect may be more specific to induced T cell 
genes. 
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Figure 2.4 Transfection of E1A constructs into primary CD4 T cells.  10x10
6
 primary CD4 T cells 
were electroporated with 2 g each of the indicated E1A constructs or a vector control using the Amaxa 
system as described in Materials and Methods.  Cells were then cultured 36 h to allow expression of the 
constructs, followed by stimulation with PMA/A23187 for 3 h.  After RNA was isolated with Trizol, cDNA 
was synthesized as described in Materials and Methods.  qPCR was performed with primers specific to a) 
CTLA-4, b) IL-2 and c) GAPDH.   Results are the averages of 3 independent experiments, presented as 
the fold over an unstimulated sample ± SEM, normalized to B2M (*p<0.05).  
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NFAT1 binding precedes histone acetylation at the CTLA-4 promoter.  NFAT1 
nuclear translocation requires activation of the calcium-dependent cytoplasmic 
phosphatase calcineurin.  Cyclosporin A inhibits calcineurin, thus blocking NFAT1 and 
preventing transcriptional activation of NFAT1-dependent genes (12).  To determine the 
sequential order of NFAT1 binding and histone acetylation at the CTLA-4 promoter in 
primary cells, we evaluated the effect of NFAT1 blockade on levels of histone 3 acetyl 
9/14 by ChIP (Figure 2.5).  Freshly isolated PBMC were either untreated or treated with 
10 ng/mL cyclosporin.  Unstimulated samples were compared to cells stimulated for 2 h 
with PMA/A23187. 
 As we have previously observed detection of NFAT1 at the CTLA-4 promoter 
increased more than 3-fold after stimulation in untreated samples (Figure2.5a).  Addition 
of cyclosporin A inhibited NFAT1 binding; measurable levels were reduced to those of 
unstimulated cells in these samples.  When we assayed for acetylated histone 3, we 
again saw a 3-fold induction with stimulation alone.  Importantly, NFAT1 blockade also 
negatively impacted the level of histone acetylation, again diminishing detection to that 
of unstimulated samples.  As the cofactor p300 is not directly activated by calcineurin, 
these data suggest histone acetylation at the CTLA-4 proximal promoter is directly 
dependent on nuclear translocation of NFAT1. 
  
77 
 
 
  
 
Figure 2.5. ChIP assay analysis of cyclosporin-treated primary PBMC. Primary PBMC were isolated 
by Ficoll preparation as described in Materials and Methods.  10x10
6 
cells were either untreated or treated 
with 10 ng/mL CyA for 30 min, after which samples were split in half and either stimulated with 
PMA/A23187 for an additional 2 h or left unstimulated followed by formaldehyde crosslinking and 
shearing by sonication.  ChIP was performed as described in Materials and Methods with antibodies to a) 
NFAT1, b) acetylated histone 3 (K9/14) and isotype control.  Crosslinks were reversed and the DNA was 
purified for amplification with primers spanning the CTLA-4 NFAT binding region at -280 bp.  Results are 
presented as the average fold over unstimulated/untreated ± SEM normalized to isotype control and are 
representative of two independent experiments (*p<0.05). 
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The p300 inhibitor curcumin blocks CTLA-4 transcription in CD4 T cells.  Our 
previous experiments have shown E1A blocks histone acetylation at the CTLA-4 
promoter, but it is not clear which HAT is involved.  Curcumin has been used to 
specifically inhibit p300 (8).  To determine whether p300 plays a role, we treated 
primary CD4 T cells with increasing concentrations of curcumin and analyzed the 
samples for mRNA expression (Figure 2.6).  CTLA-4 transcription is repressed dose-
dependently, with a significant reduction starting at 20 M (Figure 2.6a).  To establish 
whether curcumin could serve as a CTLA-4-specific inhibitor, we measured IL-2 
transcript levels in the same samples (Figure 2.6b).  Unfortunately, IL-2 expression is 
also abrogated implying curcumin may inhibit multiple aspects of the adaptive immune 
system.  The concentrations needed to suppress expression were similar for both IL-2 
and CTLA-4. 
 To be sure transcription inhibition was not global we also measured mRNA levels 
of internal control GAPDH (Figure 2.6c).  The 20 M concentration actually caused an 
increase in GAPDH expression, which was further elevated at 80 M.  The GAPDH 
gene does not appear to be regulated by p300 and may actually benefit from p300 
inhibition, as we observed a dose dependent increase in GAPDH mRNA. 
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Figure 2.6 Analysis of mRNA after p300 inhibition with curcumin.  Primary CD4 T cells were isolated 
as previously described.  5x10
6
 cells were pre-treated for 1 h with the indicated concentration of curcumin 
with 0 M serving as a DMSO vehicle control, then stimulated for 3 h with PMA/A23187.  RNA was 
isolated with Trizol and cDNA was synthesized as described in Materials and Methods.  Expression of a) 
CTLA-4, b) IL-2 and c) GAPDH was measured by qPCR as described in Materials and Methods using 
specific primers and B2M as the internal control.  Results are presented as fold over an unstimulated 
sample and are the averages of experiments with 3 independent donors ± SEM (*p<0.05, **p<0.005).   
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High concentrations of garcinol suppress CTLA-4 expression.  The HAT inhibitor 
garcinol can block both PCAF and p300, with a higher affinity for PCAF (7).  We treated 
primary CD4 T cells with increasing concentrations of garcinol and measured the effect 
on mRNA expression as we did with curcumin in Figure 2.6.  The concentrations 
necessary to block CTLA-4 were far higher for garcinol than curcumin (Figure 2.7a).  
We did not detect a significant decrease until 80 M.  IL-2 expression followed the same 
dose response and was also significantly suppressed with the 80 M treatment (Figure 
2.7b).  Again similar to curcumin we found an increase in GAPDH with 80 M garcinol 
(Figure 2.7c). 
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Figure 2.7.  Garcinol modulates mRNA expression in primary CD4 T cells.  Primary CD4 T cells were 
isolated as previously described.  5x10
6
 cells were pre-treated for 1 h with the indicated concentration of 
garcinol with 0 M serving as a DMSO vehicle control, then stimulated for 3 h with PMA/A23187.  RNA 
was isolated with Trizol and cDNA was synthesized as described in Materials and Methods.  Expression 
of a) CTLA-4, b) IL-2 and c) GAPDH was measured by qPCR as described in Materials and Methods 
using specific primers and B2M as the internal control.  Results are presented as fold over an 
unstimulated sample and are the averages ± SEM of experiments with 3 independent donors (*p<0.05). 
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DISCUSSION 
 
 The work within this chapter has not only identified an NFAT1-dependent 
cofactor involved in histone acetylation at the CTLA-4 promoter, but through the use of 
E1A proteins we show this method can be a valuable tool for studying gene regulation.  
Our initial studies used cotransfection of luciferase CTLA-4 constructs with wild-type 
and mutant E1A 12S plasmids in the leukemia cell line Jurkat.  We show that the CR1 
region, but not CR2, is capable of inhibiting CTLA-4 promoter induction.  In these 
experiments, we found the wild-type E1A 12S protein blocked luciferase activity with as 
little as 380 bp of the promoter.  As previously reported, the 264 bp promoter construct 
was inactive, and addition of E1A proteins had no effect on this region.  Use of larger 
promoter constructs did not improve luciferase production over the 380 bp alone, and 
again both the wild-type E1A and CR2 constructs abrogate promoter activity in each of 
these plasmids.  These data suggest the involved cofactor binds to CR1 and may be 
directly interacting with NFAT1. 
 During normal activation of the CTLA-4 gene, acetylation of histone 3 occurs at 
lysines 9 and 14.  Analysis utilizing chromatin immunoprecipitation (ChIP) assays in our 
Jurkat cotransfection model reveals that this histone acetylation does not occur in the 
presence of an intact CR1 region, implicating the potential involvement of HATs p300 or 
PCAF, which both interact with CR1.  Interestingly, we find acetylated histone interacts 
with the exogenous promoter even in the absence of stimulation in Jurkat cells which 
may be an artifact of our model.  Addition of 12S and CR2 E1A eliminates acetylated 
histone 3 detection in both unstimulated and stimulated cotransfected Jurkats.  When 
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we immunoprecipitate with antibodies specific to NFAT1, we find stimulation leads to 
increased NFAT1 binding.  Unlike histone acetylation, NFAT1 interaction with the CTLA-
4 promoter is not affected by E1A. 
 Given E1A suppresses histone acetylation but does not block NFAT1 interaction 
with an ectopic CTLA-4 promoter we wanted to evaluate whether histone acetylation 
would require NFAT1 at the endogenous promoter in primary cells.  Upon induction by 
PMA/A23187 stimulation, we find both NFAT1 and acetylated histone localize to the 
proximal CTLA-4 promoter.  By pre-treating cells with CyA we block NFAT1 nuclear 
translocation as evidenced by our ChIP results.  Under these conditions we also find 
histone acetylation is lost.  CyA has no direct effect on HATs, and therefore these 
results provide evidence NFAT1 binding precedes histone acetylation at the CTLA-4 
promoter.   
 Similar to our Jurkat cotransfection experiments, the wild-type 12S E1A construct 
is also capable of inhibiting CTLA-4 transcription in primary CD4 T cells.  The 12S 
construct reduced expression to approximately 50% of the control sample.  
Unexpectedly, mutation of either the CR1 or CR2 site revived CTLA-4 induction, which 
may indicate the involved cofactor is binding to both regions.  Another interesting finding 
is that the 12S E1A protein does not explicitly inhibit CTLA-4 transcription; it also 
suppresses IL-2.   Our objective in these studies is to isolate pathways specific to 
CTLA-4 in order to modulate the immune response.  The suppression of IL-2 in samples 
electroporated with the 12S E1A plasmid suggests the cofactor may be involved in 
expression of both activating and regulatory T cell genes.  The 12S construct does not 
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affect global gene expression as evidenced by transcription of GAPDH which was not 
suppressed with any of the E1A proteins. 
 E1A is known to bind histone acetyltransferases, but it also interacts with a 
variety of additional proteins.  We next targeted histone acetyltransferases with the 
specific inhibitors curcumin and garcinol to determine whether the effects of E1A 
transfection were due to p300/CBP or PCAF activity.  We are able to block transcription 
of CTLA-4 and demonstrate a role for p300 in CTLA-4 activation with curcumin and 
garcinol.  Curcumin was a far more potent CTLA-4 inhibitor in these experiments.  Both 
of these compounds inhibit HAT activity, but their dissimilar chemical structures lead to 
distinct binding affinities for HAT family members.  Curcumin was shown to selectively 
block p300/CBP without impacting PCAF (8).  Conversely, garcinol shows activity 
against p300 but has a higher potency toward PCAF (7).  As curcumin is more effective 
at suppressing CTLA-4 transcription, our data suggests p300 may be responsible for 
acetylation at the CTLA-4 promoter.   
 We also find inhibition of IL-2 transcription with curcumin and garcinol at 
equivalent concentrations as required for CTLA-4 suppression.  This again provides 
evidence that the same cofactor may be necessary for transcription of both genes.  An 
earlier study using E1A constructs found p300 was important for IL-5 expression (65).  
Both garcinol and curcumin have been shown to reduce inflammation (52, 84).  Taken 
together with our results, p300 may be a common cofactor for a variety of T cell 
cytokines.  The work in this chapter provides evidence that histone acetylation is 
necessary for CTLA-4 expression and that targeting the cofactor p300 is an effective 
method of inhibiting CTLA-4 transcription.   
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CHAPTER 3 
Topoisomerase I Modulates a Subset of Induced T Cell Genes, Including CTLA-4 
 
ABSTRACT 
 
 Upon activation, T cells immediately initiate transcription of immune modulating 
genes to appropriately direct the immune response.  The general role of DNA 
conformation in transcription, including the involvement of topoisomerase enzymes, has 
been previously explored, but whether this mechanism is specifically involved in 
induced genes remains unclear.  In effector T cells, CTLA-4 transcription is rapidly 
activated after stimulation.  Here we show topoisomerase I but not II is necessary for 
transcription of CTLA-4 and a subset of induced genes.   
 By use of the topoisomerase I-specific inhibitors camptothecin and SN-38, we 
find a dose-dependent reduction in CTLA-4 mRNA when enzymatic activity is blocked.  
CTLA-4 intracellular and extracellular protein levels are also diminished with 
topoisomerase I inhibition.  We measured expression of a panel of induced genes and 
found all of them except TNF- were also inhibited at the transcript and protein levels.  
The topoisomerase II inhibitor etoposide had no effect on induced gene expression, 
demonstrating these results are specific to topoisomerase I.  When constitutive, internal 
control genes actin and GAPDH were analyzed, these inhibitors did not modulate 
expression.  Finally, we compared camptothecin to cyclosporin A, an inhibitor of NFAT1 
nuclear translocation used clinically for immune suppression.  The collection of genes 
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affected by CyA differs from camptothecin, indicating there may be circumstances 
where use of topoisomerase I inhibition is a more ideal method of immune suppression. 
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INTRODUCTION 
 
 The previous chapter explored DNA conformation at the level of chromatin 
organization through histone modifications.  We next wanted to investigate whether 
supercoiling could play a role in CTLA-4 transcriptional regulation.  The DNA double 
helix created by base pairing is further compacted by supercoiling, a process that is 
regulated by enzymes known as gyrases or topoisomerases.  During replication, the two 
strands of DNA are unzipped by a helicase at the replication fork, resulting in highly 
coiled DNA upstream of the polymerase machinery.  Topoisomerases work to either 
relax positive supercoils or introduce negative supercoils to relieve the tension caused 
by helicase activity.   
 DNA gyrase, a prokaryotic topoisomerase, was first discovered in E. coli in 1971 
(121).  Since then, topoisomerases have been identified in eukaryotes, as well.  Aside 
from replication, these proteins have been implicated in both recombination and 
transcription (122).  The majority of evidence into how topoisomerases regulate 
transcription has been limited to bacteria and yeast studies, as well as in vitro systems 
with purified proteins and DNA.  Whether higher eukaryotes require topoisomerase 
activity for transcription is still poorly understood.  Analysis of eukaryotic cells has 
demonstrated topo I may be involved in transcriptional elongation or mRNA splicing 
(20). 
 There are two main classes of topoisomerases which are differentiated by their 
mechanisms (24).  The ATP-independent type I topoisomerases (topo I) nick one strand 
of the DNA and relax supercoils before religation.  This changes the linking number, or 
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number of times the two strands wind around each other, by single digits.  Type II 
topoisomerases (topo II) require ATP and function by cutting both DNA strands to 
change the linking number in increments of two.   
 Inhibitors to topoisomerases have proven effective in treatment of cancer due to 
the high replication rates of tumor cells (120).  Small molecule inhibitors to topo I and II 
can either cause excess cleavage of DNA or prevent religation.  Topo II can also be 
inhibited by blocking ATPase activity.  In this chapter we will utilize etoposide, a topo II 
inhibitor, and derivatives of camptothecin, a topo I inhibitor.  Camptothecin is a natural 
compound found in the bark of a Chinese tree known as the “happy tree”.  Due to its low 
solubility, the analog irinotecan was developed.  Irinotecan naturally has very little effect 
on topo I until it is activated by hydrolysis into the metabolite SN-38, a potent topo I 
inhibitor.  Blockade of topo I or topo II with these compounds has been effective in 
apoptosis induction in proliferating cancer cells.  The objective of this chapter is to 
explore the role of topoisomerase enzymes in the rapid transcriptional induction of 
CTLA-4 and other T cell genes using the described chemical inhibitors. 
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RESULTS 
 
Inhibition of topo I, not II represses CTLA-4 mRNA expression.  To determine 
whether topoisomerases are involved in CTLA-4 transcription, we isolated primary CD4 
T cells and treated them with increasing concentrations of camptothecin and etoposide 
to inhibit topo I and II, respectively (Figure 3.1).  Cells were pre-treated for 1 h prior to 
stimulation to ensure the cells had adequately taken up the compounds.  We then 
stimulated the cells for 3 h to induce CTLA-4 to its maximum level, which was 55.5-fold 
(+/- 9.8) over unstimulated cells as the average of four donors we tested.  Compared to 
DMSO alone, camptothecin significantly reduces CTLA-4 expression dose-dependently.  
With 100nM expression is suppressed to 40-fold (+/- 10.2), and 10 M treatment 
reduces transcript to 10.2-fold (+/- 2.3) on average.  With the same concentrations of 
the topo II inhibitor etoposide, we do not detect a significant effect on CTLA-4 mRNA 
levels. 
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Figure 3.1.  Topo I inhibition with camptothecin suppresses CTLA-4 transcript.  Primary CD4 T cells 
were isolated and 5x10
6
 cells were treated with each of the indicated concentrations of camptothecin or 
etoposide for 1 h prior to stimulation with PMA/A23187 for 3 h.  Total RNA was isolated with Trizol, cDNA 
was synthesized and qPCR was performed as described in Materials and Methods with primers specific 
to CTLA-4.  Results were normalized to B2M and are presented as the average fold over unstimulated 
cells from four independent experiments ± SEM (*p<0.05). 
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Camptothecin does not induce apoptosis in primary CD4 T cells.  Camptothecin 
and its derivatives have been used to target profusely replicating tumor cells for 
apoptosis.  Based on the raw data of the internal control B2M from our dose curve in 
Figure 3.1, we were confident the resulting effects were not due to apoptosis in our 
primary cell system.  To verify this experimentally, we treated cells with 0, 0.1, 10 and 
100 M camptothecin as in Figure 3.1, stimulated the cells for 3 and 6 h with 
PMA/A23187 and measured apoptosis by annexin V/PI staining (Figure 3.2a).  We find 
overall apoptosis levels increase between stimulation for 3 and 6 h, but the addition of 
camptothecin does not boost cell death over DMSO.  Treatment with 100 M, a 10-fold 
increase over the highest concentration in our mRNA dose curve, also does not impact 
programmed cell death in primary CD4 T cells. 
 To determine the effect of camptothecin on proliferating cells, and as a positive 
control for our results in Figure 3.2a, we treated Jurkat T cells with 10 M camptothecin 
or DMSO for 6 h (Figure 3.2b).  With DMSO alone, less than 10% of cells are apoptotic.  
After 6 h with 10 M camptothecin, greater than 80% of cells are undergoing 
programmed death. 
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Figure 3.2.  Apoptosis does not increase in primary CD4 T cells transiently treated with 
camptothecin.  a) Primary CD4 T cells were isolated and treated with the indicated concentrations of 
camptothecin for 1 h, followed by stimulation for 3 or 6 h as denoted on the histograms.  10
5
 treated cells 
were stained with 1 L each of annexin V or PI and positive staining was measured by flow cytometry.  
Results are presented as histograms generated by FlowJo analysis and are representative of three 
independent experiments.  b) Jurkat T cells were plated in culture at 10
6
/mL and treated with 10 M 
camptothecin or an equivalent volume DMSO for 6 h, followed by staining and analysis as in (a).  
Presented results are representative of three independent experiments. 
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Topo I inhibition suppresses CTLA-4 but not constitutive internal control genes.  
Irinotecan is a more soluble analog of camptothecin, but its activity as a topo I inhibitor 
requires its hydrolysis into the metabolite SN-38.  In addition to camptothecin, we 
treated fresh primary CD4 T cells with irinotecan and SN-38 to determine the effect on 
transcription (Figure 3.3).  The calcineurin inhibitor cyclosporin A (CyA) was included as 
a control for CTLA-4 inhibition and etoposide demonstrates the specificity to topo I.  
CTLA-4 was suppressed with both camptothecin and SN-38, but not the inactive topo I 
inhibitor irinotecan (Figure 3.3a).  The topo I inhibitors repressed CTLA-4 expression to 
the same degree as CyA (p<0.05).  Etoposide again had no impact on CTLA-4 
expression. 
 Previous studies have suggested topoisomerase is necessary for the elongation 
phase of transcription (20), which would imply all genes would be affected by our 
inhibitors.  We next measured mRNA expression levels of NFAT1 (Figure 3.3b), Actin 
(Figure 3.3c) and GAPDH (Figure 3.3d).  We find the topoisomerase inhibitors have no 
effect on any of these three non-induced genes.  The fact that NFAT1 mRNA is 
unaffected by topo I inhibition supports that this enzyme directly modulates CTLA-4 
activation.   
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Figure 3.3. SN-38 and camptothecin inhibit CTLA-4 induction but not constitutive genes.  Primary 
CD4 T cells were isolated and 5x106 cells were treated with 10 g/mL CyA or M camptothecin, SN-
38, irinotecan, etoposide or DMSO as indicated for 1 h prior to stimulation with PMA/A23187 for 3 h.  
Total RNA was isolated with Trizol and cDNA was synthesized as detailed in Materials and Methods.  
Samples were analyzed by qPCR using primer sets specific to a) CTLA-4, b) NFAT1, c) Actin or d) 
GAPDH with normalization to B2M.  Results are the averages of three independent experiments ± SEM 
and represent the fold increase over an unstimulated sample (*p<0.05).  
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CTLA-4 protein expression is reduced with topo I inhibitors.  We find that CTLA-4 
transcript induction decreases dramatically but incompletely with topo I inhibitors, so we 
next measured protein expression in primary CD4 T cells to determine the degree of 
inhibition at this level (Figure 3.4).  By immunoblot with whole cell extracts we find 
strong induction of CTLA-4 with stimulation alone.  Addition of CyA blocks expression 
almost entirely, while camptothecin inhibits CTLA-4 to a slightly lesser degree.  
Treatment with etoposide has no effect on CTLA-4 and irinotecan also does not impede 
expression. 
 As a more quantitative method, we next assayed cells for surface (Figure 3.5a) 
and intracellular (Figure 3.5b) CTLA-4 expression by flow cytometry.  Consistent with 
the immunoblot results, CTLA-4 protein is minimal in unstimulated cells at both the 
intracellular and extracellular level.  Stimulation induces expression, which can be 
blocked with CyA or the topo I inhibitors camptothecin and SN-38.  The topo I inhibitors 
were slightly less efficient at suppressing CTLA-4 than CyA.  Etoposide and irinotecan 
do not impede either intracellular or surface CTLA-4.  
 To establish whether topo I inhibition affects NFAT1 activation or overall protein 
levels we also probed our immunoblot membrane with an antibody specific to NFAT1 
(Figure 3.4).  Two species of NFAT1 exist, a higher molecular weight band for the 
phosphorylated, inactive form and a lower band for the dephosphorylated protein.  As 
expected, the unstimulated sample has a higher band than the stimulated sample.  CyA 
treatment not only blocks dephosphorylation, but also diminishes total NFAT1 protein.  
The topoisomerase inhibitors do not eliminate NFAT1, nor do they impede 
dephosphorylation.  
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Figure 3.4.  Protein analysis of CD4 T cells treated with topoisomerase inhibitors by immunoblot.  
Primary CD4 T cells were isolated and treated with 10 g/mL CyA or 10 M camptothecin, etoposide or 
irinotecan as indicated for 1 h prior to stimulation for 3 h with PMA/A23187.  Total cell lysate was isolated 
by lysis with RIPA buffer as described in Materials and Methods.  Proteins were quantified and 30g of 
each sample was separated on a 10% acrylamide gel, transferred to PVDF and probed with antibodies 
specific to CTLA-4 or NFAT1 as detailed in Materials and Methods.  Actin serves as a loading control.  
These results are representative of three independent experiments. 
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Figure 3.5.  Flow cytometric analysis of CTLA-4 expression in CD4 T cells treated with 
topoisomerase inhibitors.  Primary CD4 T cells were isolated and treated with 10 g/mL CyA or 10 M 
camptothecin, etoposide or irinotecan as indicated for 1 h prior to stimulation for 3 h with PMA/A23187.  
a) 10
6
 cells were stained with 1 L PE-conjugated CTLA-4 antibody and analyzed by flow cytometry as 
described in Materials and Methods.  b) 10
6
 cells were fixed/permeablized and stained with 1 L PE-
conjugated CTLA-4 antibody followed by analysis by flow cytometry for intracellular CTLA-4 as described 
in Materials and Methods.  Analysis of the results from (a) and (b) was conducted with FlowJo and the 
presented histograms are representative of 3 independent experiments. 
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Topo I inhibitors repress many but not all induced T cell genes.  To determine 
whether topo I inhibition exclusively represses CTLA-4 transcription we measured 
mRNA expression of additional induced T cell genes using the samples from Figure 3.6.  
We find IL-2 (Figure 3.6a), IFN- (Figure 3.6b) and IL-4 (Figure 3.6c) follow the same 
trend as CTLA-4, where both camptothecin and SN-38 potently inhibit transcription to 
nearly the same degree as CyA.  Interestingly, TNF- is unaffected by topo I inhibition, 
while CyA blocks expression (Figure 3.6d).  Conversely, the p50 subunit of NFB is not 
affected by CyA but induction is repressed with topo I inhibitors.  As with each of the 
previously measured transcripts, expression levels of all of these genes are unchanged 
with etoposide or irinotecan. 
 
Inhibition of topo I modulates cytokine secretion in primary CD4 T cells.  Given the 
transcript levels of many of the cytokines were reduced, we wanted to evaluate the 
effect of topo I inhibition on secreted protein levels.  We utilized a flow cytometry based 
assay to measure cytokine levels in culture media of treated and stimulated cells.  
Similar to an ELISA, this system uses capture beads to bind and detect each antigen 
which are then analyzed by flow.  Protein concentrations are then calculated based on a 
standard curve of antigen at known concentrations.  Using this assay, we find the 
secreted proteins follow the expression trend we detected for transcript levels (Figure 
3.7).  As expected, irinotecan and etoposide did not impact protein secretion.  
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Figure 3.6. SN-38 and camptothecin inhibit many but not all induced genes.  Primary CD4 T cells 
were isolated and 5x10
6
 cells were treated with 10 g/mL CyA or M camptothecin, SN-38, irinotecan, 
etoposide or DMSO as indicated for 1 h prior to stimulation with PMA/A23187 for 3 h.  Total RNA was 
isolated with Trizol and cDNA was synthesized as detailed in Materials and Methods.  Samples were 
analyzed by qPCR using primer sets specific to a) IL-2, b) IFN-, c) IL-4, d) TNF- or e) NFB p50with 
normalization to B2M.  Results are the averages of three independent experiments ± SEM and represent 
the fold increase over an unstimulated sample (*p<0.05).  
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Figure 3.7.  Cytokine secretion is suppressed with topo I inhibition.  Primary CD4 T cells were 
isolated and plated at 2x10
6
 cells/mL.  Samples were treated with 10 g/mL CyA or M camptothecin, 
SN-38, irinotecan, etoposide or DMSO as indicated for 1 h prior to stimulation with PMA/A23187 for 3 or 6 
h.  Culture supernatant was collected and analyzed by cytometric bead array as described in Materials 
and Methods.   Samples were quantified based on a standard curve of known antigen concentrations.  
Presented results are the averages of four independent experiments ± SEM (*p<0.05, **p<0.005). 
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DISCUSSION 
 
 This chapter has identified a novel role for topoisomerases in the rapid induction 
of certain T cell genes including CTLA-4.  It was previously thought that topoisomerase 
enzymes may take part in transcription, but compelling evidence has remained elusive.  
We show here that involvement of topoisomerase hinges on the nature of the gene in 
question.  Our results suggest constitutive genes do not require topological 
modifications to the DNA, while a certain class of induced genes utilizes DNA 
conformation as a means of regulation.  Through use of specific inhibitors, we find topo I 
activity, but not topo II, is necessary for expression of these genes.  Manipulation of this 
pathway can be a valuable tool for immune regulation, particularly given the group of 
genes suppressed with topo I inhibitors differs from those blocked by CyA. 
 Primary T cells present a convenient opportunity in studying topoisomerase 
function.  Cells that are freshly isolated are quiescent, requiring stimulation to promote 
cell proliferation.  Most previous studies tried to demonstrate a role for topoisomerase in 
transcription using cell lines.  This is problematic because cell lines freely replicate, 
making them targets for apoptosis when topoisomerases are inhibited.  High 
concentrations were required to see any effect on transcription (40), which was not the 
case in our studies.  The alternative was to use an artificial in vitro system with purified 
proteins and DNA, which has shown topo I cooperates at the site of transcription 
initiation, but it  does not represent an accurate depiction of what normally occurs within 
a cell and in vivo studies have had a difficult time reproducing the results (103).  Aside 
from the issue of replication and apoptosis clouding results, part of the obscurity may be 
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due to the fact that constitutive genes have been the focus of these studies, where we 
find only induced genes require topo I.  Taken together, we have shown primary T cells 
are an ideal system for studying topoisomerase in transcription due to the lack of 
replication and the abundance of inducible genes. 
 Aside from initiation, topoisomerase has also been implicated in both the 
elongation phase of transcription, particularly for longer transcripts, as well as the 
processing of mRNA by splicing (20).  Our results suggest elongation in general does 
not involve topo I since the constitutive genes we examined were not affected by 
inhibitors.  We examined NFAT1 expression, which has a long primary transcript of 
roughly 150 kbp with multiple introns.  Not only is the transcript unaffected but protein 
levels also do not change with camptothecin.  From these data we can conclude that 
elongation, even for longer transcripts, does not always depend on topoisomerase 
activity.  Topoisomerase involvement in splicing is also unlikely given our results with 
NFAT1, which has multiple splice sites.  We do not know the exact mechanism of action 
for induced genes.  It is plausible that the elongation phase of transcription requires 
topoisomerase for these genes but further experiments will be necessary to establish 
this conclusively.  Another possibility is that the conformation of DNA may be too 
constrained to allow necessary transcription factors or the RNA polymerase complex to 
bind for transcription initiation. 
 In addition to small molecule inhibitors, we sought to deplete topo I with siRNA.  
As it can be technically challenging to transfect primary T cells with high enough 
efficiency, our efforts did not result in adequate reduction of topo I protein and we did 
not detect any change in induced gene expression.  Instead we used two related but 
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chemically distinct topo I inhibitors, camptothecin and SN-38, to verify the specificity of 
our results. 
 Mondal et al demonstrated topo II is also involved in transcription (75).  As both 
topo I and II have functions in replication in prokaryotes, yeast and higher eukaryotes, it 
would not be surprising to find overlapping roles in transcription also.  We used 
etoposide, a potent topo II inhibitor that was shown by Mondal et al to inhibit chromatin-
associated DNA transcription in vitro and detected no reduction in transcription for any 
of the genes we measured. 
 The topo I inhibitor irinotecan is an improvement over camptothecin due to its 
higher solubility in aqueous solutions.  This compound itself has 100-fold less inhibitory 
ability than its hydrolyzed metabolite SN-38.  Bioactivation of irinotecan into SN-38 
requires the activity of carboxylesterases (104).  When we treat our primary CD4 T cells 
with irinotecan we do not observe any effect on transcription, though an equivalent 
molar concentration of SN-38 inhibits a select group of induced genes.  This implies 
primary T cells do not have the necessary enzymes to convert irinotecan into SN-38, an 
observation which needs to be recognized for in vitro studies. 
 As expected, when transcript levels of the cytokines IL-2, IFN- and IL-4 are 
blocked by topo I inhibition, we detect a decrease in protein secretion in the culture 
media.  The inhibitor does not have an effect on the secretory pathway, though, based 
on our results with TNF-.  This gene is neither altered at the transcript level or in its 
protein secretion by topo I inhibition.  This data indicates topoisomerase inhibition only 
represses a particular subset of induced genes and also does not impact cellular protein 
processing. 
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 When we compare T cell gene inhibition with CyA to topo I inhibitors we find 
these compounds suppress different sets of genes.  CyA is used for transplant patients 
to suppress the immune response and prevent graft rejection.  It has also shown 
efficacy in the treatment of autoimmunity.  The robust suppression of immune activation 
with CyA leaves patients susceptible to infection.  Though topo I inhibitors have been 
used in cancer therapy, their capacity in immune regulation has not been investigated.  
We show many adaptive immunity cytokines are inhibited while the innate immunity 
cytokine TNF- remains inducible.  More work will be required, but if topo I inhibitors 
can be used to dampen adaptive immunity without hindering the innate response they 
could become a valuable tool for autoimmunity and transplant with a reduced risk of 
infection. 
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GENERAL CONCLUSIONS 
 
 A delicate balance exists in achieving sufficient activation of the immune system 
without allowing the response to continue unrestrained.  Many current cancer therapies 
strive to enhance immunity through use of vaccines and pro-inflammatory cytokines in 
an effort to clear malignancy.  Recently immune regulatory pathways have become 
therapeutic targets with the goal of obstructing immune suppression, thus enhancing 
activation.  For example, monoclonal antibodies to NK cell inhibitory KIR molecules as 
well as T cell regulators PD-1 and CTLA-4 have been investigated experimentally and in 
clinical trials with considerable promise.  In the case of CTLA-4, antibody blockade has 
been a successful cancer treatment, but rampant autoimmunity is all too commonly a 
life threatening side effect.  CTLA-4 is constitutively expressed on the surface of Tregs 
and is also induced in effector T cells upon activation.  The work of this dissertation has 
focused on the transcriptional regulation of induced CTLA-4 with the intent to identify 
pathways to specifically modulate CTLA-4 expression in effector T cells.  Ideally down 
regulation of this gene in these cells would lead to an enhanced immune reaction to 
tumor with reduced risk of autoimmune side effects. 
 Conversely, for patients with autoimmunity it would be valuable to augment 
CTLA-4 expression to quell the uncontrolled immune response.  Similar challenges exist 
for transplant patients where the goal is to reduce the likelihood of graft rejection.  
Current therapies block inflammatory cytokines with monoclonal antibodies and 
inhibitors to transcription factors such as CyA, which blocks NFAT nuclear translocation.  
A CTLA-4 immunoglobulin fusion protein has also shown promise in the treatment of 
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rheumatoid arthritis, demonstrating the potency of CTLA-4 in an autoimmune setting.  
By increasing CTLA-4 cell surface expression through modulation of transcription, we 
may be able to attain more effective suppression of the overactive immune system. 
 We have shown CTLA-4 is elevated in malignant cells of patients with CTCL both 
here and previously (126), which presents an interesting opportunity to investigate how 
these cells differentially regulate expression of this gene.  Not only could the pathways 
used by CTCL cells be targeted to decrease CTLA-4 expression and hopefully revive 
the anti-tumor immune response, but we can also learn from how these cells augment 
CTLA-4 transcription and perhaps exploit this mechanism for treatment of both 
autoimmunity and organ and tissue transplant.  Using CTCL as a guide, we have 
identified a novel method for CTLA-4 regulation where proteasome inhibition leads to 
elevated expression.   
 Our initial experiments found an increase in polyubiquitinated proteins in cell 
lysates from CTCL patients.  The proficiency of the 26S proteasome pathway had not 
previously been investigated in CTCL.  Our ubiquitin results suggest either improper 
function of a component within the proteasome pathway or excessive accumulation of 
extraneous or misfolded proteins.  Due to its involvement in immune monitoring, the 
proteasome is targeted by viruses including Epstein-Barr to avoid recognition by 
cytotoxic T cells (32).  CTCL may be functioning in a similar manner, but further 
experiments will be required to determine this.  We isolated the single entity of 
proteasome dysfunction by using specific inhibitors in normal CD4 T cells and found 
that this caused an increase in CTLA-4 transcription.  We identified GATA3 as a 
necessary factor in augmentation of CTLA-4 in the presence of proteasome inhibitors, 
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and this transcription factor is also elevated in CTCL.  Further experiments will be 
required to determine whether GATA3 may be responsible for the CTLA-4 increase we 
observe in CTCL.  If this is the case, GATA3 could prove to be a valuable therapeutic 
target. 
 Within this work and in combination with our previous study we have established 
NFAT1 and GATA3 are important transcription factors that promote CTLA-4 induction 
(41).  Our data also suggests NFB does not contribute to or suppress CTLA-4 
expression.  GATA3 may be involved only under specific circumstances while NFAT1 is 
a requirement for CTLA-4 transcription.  We were not able to identify a role for GATA3 
in CTLA-4 expression in the absence of proteasome inhibitors, though published work 
by van Hamburg, et al shows higher CTLA-4 in a GATA3 over-expressing mouse model 
(115).  Additional expression vector studies with longer term GATA3 overexpression 
may be a better system for human primary CD4 T cells, but from our transient data it 
does not appear CTLA-4 is enhanced simply with elevated GATA3 protein.  Specific 
signaling may also be required. 
 Our kinase inhibitor results suggest the p38 pathway is responsible for GATA3 
phosphorylation and this pathway is also activated by proteasome inhibition.  This may 
in part explain why addition of GATA3 alone does not increase CTLA-4.  It may also 
help explain our sorted cell data where cells expressing GATA3 transcript were not 
destined to express CTLA-4.  We did not evaluate kinase activity in these samples, 
which could be an important future experiment.  Altogether, these data provide evidence 
that the p38 pathway may be a valuable therapeutic target.  We show IFN- expression 
is unaffected, while CTLA-4 and Th2 cytokine IL-4 are both suppressed with p38 
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inhibition.  Both IL-4 and CTLA-4 behave similarly in these experiments, again 
suggesting CTLA-4 is a Th2-associated gene.  Treatment with SB203580 or an 
alternative compound could support a pro-inflammatory immune response, which would 
be more valuable with cancer therapies. 
 Aside from the impact on CTLA-4 expression, it is important to note proteasome 
inhibition, through its increase in the Th2 transcription factor GATA3 and blockade of 
pro-inflammatory NFB, can promote a Th2 phenotype.  We measure a decrease in 
transcription of IFN- while IL-4 levels rise.  Bortezomib has more recently been used for 
GVHD treatment and prevention (107), but the mechanism behind this effect remains 
unclear.  Our results shed light on the shift from Th1 to Th2 that bortezomib can induce, 
which in addition to increased CTLA-4 could account for the protective phenotype 
created by bortezomib to treat GVHD.  Other inflammatory diseases could benefit from 
bortezomib, as well, but further studies will be necessary.  Currently clinical trials are 
focused on using this drug to treat a variety of malignancies, but its influence on the 
immune response should also be exploited. 
 As mentioned previously, this work has focused on induced CTLA-4 and not the 
constitutive expression found in Tregs.  FoxP3 is the most consistent marker for Tregs 
currently known.  In the case of proteasome inhibition, we find FoxP3 protein levels are 
depleted in the CD4 population, indicating the CTLA-4 we measure is strictly expressed 
on effector T cells.  This is important for our mechanistic studies, but it also has 
implications for understanding regulation of Tregs.  It is unclear how proteasome 
inhibition leads to a reduction in FoxP3 or if this could be an efficient mechanism of Treg 
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depletion.  Further experiments including in vivo analysis would be valuable to 
determine the effects of proteasome inhibition on other immune cell types. 
 Aside from transcription factors, epigenetic modification in the form of histone 
acetylation is necessary to induce CTLA-4 expression, as well.  This may serve to open 
the chromatin conformation to allow transcriptional machinery to access the promoter.  
We find NFAT1 binding precedes and is required for histone acetylation, suggesting the 
HAT cofactor may interact directly with NFAT1.  From our data we can infer p300 is 
likely the HAT responsible for acetylation at the CTLA-4 promoter.  Interestingly, our 
E1A and inhibitor experiments affected CTLA-4 and IL-2 in a similar manner.  A 
previous report found p300 functions at the IL-5 promoter, as well (65).  These and 
other induced T cell genes, though different in function, may share key steps in their 
activation.  If HAT activity is dependent on transcription factor binding for these genes 
as it is for CTLA-4, the ultimate regulator may be whether transcription factors are able 
to access the promoter. 
 In addition to packaging of genomic DNA into chromatin by its wrapping around 
nucleosomes, the actual topology of the DNA can also be modified to regulate 
transcription of certain genes.  In humans, topoisomerases have only loosely been 
associated with transcription, though stronger evidence has been reported for 
prokaryotes and yeast.  We have shown here that transcription of constitutive genes is 
not impacted by topoisomerase inhibition in primary CD4 T cells, while induced genes 
require topo I activity.  Under normal circumstances T cells are in a quiescent state until 
they are stimulated.  Upon T cell receptor engagement the immune response is quickly 
activated to clear the responsible pathogen.  A cascade of kinase signaling as well as 
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calcium influx ultimately leads to the activation of transcription factors and production of 
a repertoire of cytokines and chemokines to direct the immune response appropriately 
for the type of pathogen involved.  Though the activation of transcription factors plays a 
critical role in the instantaneous induction of many of these genes, we questioned 
whether the degree of supercoiling in the DNA could also be involved.  Resting T cells 
provide an excellent model for these experiments because in addition to constitutively 
active genes, they can be stimulated to express many inducible genes.  Our results 
using specific inhibitors in vivo define a novel mechanism for topo I, where only a 
distinct subset of CD4 T cell genes, including CTLA-4, requires topoisomerase activity.  
As these data support that topo I is not utilized globally for transcription, it is our 
hypothesis that induction of these genes requires relaxation of the DNA to rapidly 
initiate expression.  Further experiments will be valuable in determining the exact 
mechanism for topoisomerase at these promoters. 
 Inhibitors to both topo I and II are used clinically in cancer therapies due to their 
increased cytotoxicity to highly proliferant tumor cells.  Our results provide insight to 
immune capabilities in the presence of these compounds.   Topo II inhibitors may be 
more favorable therapeutically as they target replicating cells without having an impact 
on the immune system’s cytokine induction.  The use of topo I inhibitors may impede 
the immune response and reduce the rate of tumor clearance by suppressing critical 
immune signaling.  Alternatively, the use of topo I inhibitors to modulate the immune 
response for autoimmunity and transplant should be investigated.  The panel of genes 
affected by topo I inhibitors varies from those blocked by CyA.  As a result it should be 
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explored whether compounds directed at topo I provide more benefit than current 
therapies for immune suppression. 
 This dissertation has focused on mechanisms regulating CTLA-4 transcription.  A 
2004 study found CTLA-4 was internalized in endosomes in T cell clones and only after 
stimulation would the protein bud to the cell surface (53).  They report that CTLA-4 is 
pre-formed in the T cell lines they developed, which suggests trafficking is the chief 
mechanism controlling cell surface expression.  As previously mentioned, their model 
uses T cells that are expanded with IL-2 and CD3 antibody, thus activating the cells.  
Though intracellular trafficking is an important component of CTLA-4 regulation, our 
results demonstrate CTLA-4 is not present at considerable levels in freshly isolated 
unstimulated T cells.  This work has utilized primary, resting T cells to study CTLA-4.  
We find by immunoblot and intracellular flow cytometry that baseline levels of CTLA-4 
protein are nearly undetectable.  Given we did not deplete Tregs from our CD4 T cell 
population it is plausible the CTLA-4 we do find in our unstimulated samples is from 
constitutive expression within the Treg subset but additional experiments would be 
necessary to support this.  It is from our data that we conclude transcription induction is 
the fundamental switch determining CTLA-4 expression in effector CD4 T cells. 
 Our goal is to find pathways unique to CTLA-4 transcription that can be exploited 
to modulate the immune response.  Through the use of bortezomib we are able to 
increase both CTLA-4 mRNA and surface expression to ultimately suppress T cell 
proliferation in a CTLA-4-dependent manner.  These results provide direct evidence that 
simply altering CTLA-4 transcription is sufficient to modify the immune response.  We 
have defined three distinct levels of CTLA-4 transcriptional regulation which could be 
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useful targets to adjust T cell activity accordingly for a variety of immune-mediated 
diseases.  Though histone acetylation and topo I involvement did not prove specific to 
CTLA-4, they can be manipulated to control the immune response.  Our proteasome 
inhibition results suggest GATA3 may be a key component that would be specific to 
CTLA-4 and the Th2 phenotype without affecting the Th1 response.  Through use of 
proteasome inhibitors or compounds specifically directed at GATA3 or its activation it 
may be possible to guide T cell activity to be active or suppressive.  The discussed 
transcriptional mechanisms should be investigated further for their use in autoimmune, 
transplant and cancer therapies.  
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ABSTRACT 
CTLA-4 TRANSCRPTIONAL ACTIVATION: 
REGULATION OF INDUCED EXPRESSION 
by 
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Advisor: Dr. Henry K. Wong 
Major: Immunology and Microbiology 
Degree: Doctor of Philosophy 
 Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a T cell surface protein that is 
homologous to CD28 and binds to the B7 family of ligands.  Unlike CD28, CTLA-4 
interaction transmits a negative signal in T cells, leading to suppression of proliferation.  
CTLA-4 is constitutively expressed on regulatory T cells (Tregs) but is also inducible in 
effector T cells.  The mechanisms driving transcriptional regulation of CTLA-4 are poorly 
understood.  Our previous work identified a bona fide NFAT1 binding site in the 
proximal promoter for effector T cells.  In addition, we found histone acetylation 
occurred after stimulation. 
 As a result of its role in suppressing T cell proliferation, CTLA-4 is important for 
regulation of T cell responses.  CTLA-4-immunoglobulin fusion proteins have shown 
efficacy to quell the overactive immune system in various types of autoimmune 
diseases.  Alternatively, blocking antibodies to CTLA-4 have been used in cancer 
therapies to boost the anti-tumor immune response.  Malignant cells of cutaneous T cell 
lymphoma (CTCL) express elevated levels of CTLA-4, which may contribute to reduced 
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tumor immunity as the disease progresses.  The objective of this work was to identify 
mechanisms of transcriptional regulation of CTLA-4 to better understand how this gene 
can be modulated to potentially cater the immune response for a variety of immune-
mediated diseases. 
 The major findings of this work include a mechanism by which proteasome 
inhibition augments CTLA-4 transcription in normal primary human CD4 T cells.  The 
Th2 associated transcription factor GATA3 is both elevated and activated by 
phosphorylation after treatment with the proteasome inhibitor bortezomib, which in turn 
leads to CTLA-4 transcriptional activation in primary CD4 T cells.  This finding may in 
part explain the increase in CTLA-4 found in CTCL, where GATA3 is also more 
abundant, particularly in its phosphorylated state.  The increased CTLA-4 in our primary 
cell model is capable of suppressing T cell proliferation, demonstrating the potency of 
transcriptional modulation of this gene.  Additionally we explored epigenetic and 
topological modifications that occur for CTLA-4 activation.  We found the histone 
acetyltransferases p300 is responsible for histone 3 acetylation at the CTLA-4 promoter, 
and its activity is required for CTLA-4 transcription.  We also discovered a previously 
undiscovered role for topoisomerase I in expression of a variety of induced genes, 
including CTLA-4.  These results define novel mechanisms governing transcriptional 
activation of CTLA-4 in human effector CD4 T cells. 
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